<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VALGANCICLOVIR- valganciclovir hydrochloride tablet, film coated </strong><br>American Health Packaging<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use valganciclovir safely and effectively. See full prescribing information for valganciclovir.  <br>VALGANCICLOVIR Tablets USP, for oral use <br>Initial U.S. Approval: 2001 </div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: HEMATOLOGIC TOXICITY, CARCINOGENICITY, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">TERATOGENICITY</span>, AND<br>IMPAIRMENT OF FERTILITY</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Clinical toxicity of valganciclovir which is metabolized to ganciclovir includes <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></span><span class="Bold"><a href="#_5cd95167-f74b-ca07-7652-0134728a2dd2">(5.1)</a></span>.</dd>
<dt>•</dt>
<dd><span class="Bold">In animal studies, ganciclovir was carcinogenic, teratogenic, and caused aspermatogenesis (<a href="#_06a3bb9b-72b3-372c-7d37-5d7e4c0fb67f">5.2</a>, <a href="#_bf09797e-c0bf-46f1-6c27-2130536e9d66">5.3</a>, <a href="#_25475139-aac8-fedb-01b6-4e9931bdae5c">5.4</a>).</span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: HEMATOLOGIC TOXICITY, CARCINOGENICITY, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">TERATOGENICITY</span>, AND<br>IMPAIRMENT OF FERTILITY</h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Clinical toxicity of valganciclovir which is metabolized to ganciclovir includes <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></span><span class="Bold"><a href="#_5cd95167-f74b-ca07-7652-0134728a2dd2">(5.1)</a></span>.</dd>
<dt>•</dt>
<dd><span class="Bold">In animal studies, ganciclovir was carcinogenic, teratogenic, and caused aspermatogenesis (<a href="#_06a3bb9b-72b3-372c-7d37-5d7e4c0fb67f">5.2</a>, <a href="#_bf09797e-c0bf-46f1-6c27-2130536e9d66">5.3</a>, <a href="#_25475139-aac8-fedb-01b6-4e9931bdae5c">5.4</a>).</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Valganciclovir tablet USP is a cytomegalovirus (CMV) nucleoside analogue DNA polymerase inhibitor indicated for:  </p>
<p class="Highlighta"><span class="Underline">Adult Patients </span><a href="#_ab954377-2249-c26e-5b9b-5de6cf7a2f8d">(1.1)</a> </p>
<dl>
<dt>•</dt>
<dd>Treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> in patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS). </dd>
<dt>•</dt>
<dd>Prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk. </dd>
</dl>
<p class="Highlighta"><span class="Underline">Pediatric Patients </span><a href="#_497aa9c7-ee17-2f61-7629-34f04737f9c6">(1.2)</a> </p>
<dl>
<dt>•</dt>
<dd>Prevention of CMV disease in kidney or heart transplant patients at high risk.</dd>
</dl>
<p class="Highlighta"><span class="Underline">Limitations of Use </span><a href="#_0248e78d-f036-6a15-65db-1e52d4d3efb4">(1.3)</a> </p>
<dl>
<dt>•</dt>
<dd>Valganciclovir tablets USP are not indicated for use in either adult or pediatric liver transplant patients. </dd>
<dt>•</dt>
<dd>The safety and efficacy of valganciclovir tablets USP have not been established for:<p class="Highlighta">- Prevention of CMV disease in solid organ transplants other than those indicated. </p>
<p class="Highlighta">- Prevention of CMV disease in pediatric solid organ transplant patients &lt; 4 months of age.  </p>
<p class="Highlighta">- Treatment of congenital CMV disease. </p>
</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<table width="100%">
<col width="38%">
<col width="62%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="Highlighta"><span class="Bold">Adult Dosage <a href="#_0fefa25e-de81-0837-0182-295b5bf2830e">(2.2)</a></span> </p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">Treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="Highlighta">Induction: 900 mg (two 450 mg tablets) twice a day for 21 days  </p>
<p class="Highlighta">Maintenance: 900 mg (two 450 mg tablets) once a day </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">Prevention of CMV disease in heart or kidney-pancreas transplant patients </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta">900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 100 days post-transplantation </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="Highlighta">Prevention of CMV disease in kidney transplant patients </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta">900 mg (two 450 mg tablets) once a day within 10 days of transplantation until 200 days post-transplantation </p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="Highlighta"><span class="Bold">Pediatric Dosage <a href="#_423e083e-18b4-6f88-1e63-91d42ec55a0a">(2.3)</a></span> </p></td></tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta">Prevention of CMV disease in kidney or heart transplant patients 4 months to 16 years of age </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="Highlighta">Dose once a day within 10 days of transplantation until 100 days post-transplantation according to dosage algorithm (note the calculation of creatinine clearance using a modified Schwartz formula in children 1 to &lt; 2 years of age </p></td>
</tr>
</tbody>
</table>
<dl>
<dt>•</dt>
<dd>Valganciclovir tablets USP should be taken with food (<a href="#_61051f57-8ca3-f04c-82c8-4ab291b78984">2.1</a>, <a href="#PHARMACOKINETICS">12.3</a>). </dd>
<dt>•</dt>
<dd>Valganciclovir tablets USP cannot be substituted for ganciclovir capsules on a one-to-one basis (<a href="#_61051f57-8ca3-f04c-82c8-4ab291b78984">2.1</a>, <a href="#PHARMACOKINETICS">12.3</a>). </dd>
<dt>•</dt>
<dd>Valganciclovir tablets USP should not be broken or crushed (<a href="#_ec90ff32-b383-1436-9a6c-397a64a00482">2.6</a>).</dd>
<dt>•</dt>
<dd>Adult patients should use valganciclovir tablets, not valganciclovir for oral solution (<a href="#_61051f57-8ca3-f04c-82c8-4ab291b78984">2.1</a>).</dd>
</dl>
<p class="Highlighta">Adults with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Adjust dose based on creatinine clearance. For adult patients receiving hemodialysis a dose recommendation cannot be given (<a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">2.5</a>, <a href="#_f3d1b9d3-b7be-40a3-5fb1-826576d0e996">8.6</a>, <a href="#PHARMACOKINETICS">12.3</a>). </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Tablets: 450 mg <a href="#DOSAGE_FORMS_AND_STRENGTHS">(3)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to valganciclovir or ganciclovir <a href="#CONTRAINDICATIONS">(4) </a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Hematologic effects: Severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have occurred with the use of valganciclovir or ganciclovir. Do not administer valganciclovir if absolute neutrophil count is &lt; 500 cells/μL, platelet count is &lt; 25,000/μL, or hemoglobin is &lt; 8 g/dL. Use with caution in preexisting <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> and when receiving myelosuppressive drugs or irradiation. Monitor with frequent testing of platelet and complete blood counts <a href="#_5cd95167-f74b-ca07-7652-0134728a2dd2">(5.1)</a>. </dd>
<dt>•</dt>
<dd>Impairment of fertility: Based on animal studies, valganciclovir may cause temporary or permanent inhibition of spermatogenesis <a href="#_06a3bb9b-72b3-372c-7d37-5d7e4c0fb67f">(5.2)</a>. </dd>
<dt>•</dt>
<dd>Teratogenesis and mutagenesis: Based on animal studies, valganciclovir is potentially teratogenic and mutagenic. Women of childbearing potential should use contraception during and following treatment and men should practice barrier contraception during and following treatment <a href="#_bf09797e-c0bf-46f1-6c27-2130536e9d66">(5.3)</a>. </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span>: <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> may occur in elderly patients (with or without reduced renal function), patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients or those taking nephrotoxic drugs, reduce dosage in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and monitor renal function (<a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">2.5</a>, <a href="#_596b1619-3216-1d4a-b463-3bab59bc7cf2">5.5</a>, <a href="#GERIATRIC_USE">8.5</a>, <a href="#_f3d1b9d3-b7be-40a3-5fb1-826576d0e996">8.6</a>, <a href="#PHARMACOKINETICS">12.3</a>). </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>•</dt>
<dd>Adult patients: Most common adverse events and laboratory abnormalities (reported in at least one indication by ≥ 20% of patients) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">graft rejection</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <a href="#_0e93312a-51dd-d412-21f8-b0edc769c1e1">(6.1)</a>.</dd>
<dt>•</dt>
<dd>Pediatric patients: Most common adverse events and laboratory abnormalities (reported in &gt; 10% of pediatric solid organ transplant recipients) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (<a href="#_28a725fb-a1ac-9c41-06f1-2b3b548ee593">6.2</a>).  </dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch </span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Zidovudine: Potential to cause <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Monitor with frequent tests of white blood cell counts with differential and hemoglobin levels <a href="#DRUG_INTERACTIONS">(7)</a>. </dd>
<dt>•</dt>
<dd>Probenecid: May increase ganciclovir levels. Monitor for evidence of ganciclovir toxicity <a href="#DRUG_INTERACTIONS">(7)</a>. </dd>
<dt>•</dt>
<dd>Mycophenolate mofetil (MMF): May increase ganciclovir concentrations and levels of MMF metabolites in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Monitor for ganciclovir and MMF toxicity <a href="#DRUG_INTERACTIONS">(7)</a>. </dd>
<dt>•</dt>
<dd>Didanosine: May increase didanosine concentrations. Monitor for didanosine toxicity <a href="#DRUG_INTERACTIONS">(7).</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: Based on animal data, valganciclovir may cause fetal harm <a href="#PREGNANCY">(8.1)</a>. </dd>
<dt>•</dt>
<dd>Nursing mothers: May cause adverse events in nursing infants. Discontinue drug or nursing, taking into consideration the importance of drug to mother <a href="#NURSING_MOTHERS">(8.3)</a>. </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: HEMATOLOGIC TOXICITY, CARCINOGENICITY, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">TERATOGENICITY</span>, AND<br>IMPAIRMENT OF FERTILITY</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Adult Patients </a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Pediatric Patients</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Limitations of Use </a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Dosing Information </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Adult Patients With Normal Renal Function</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Pediatric Patients </a></h2>
<h2><a href="#section-2.4" class="toc">2.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h2><a href="#section-2.5" class="toc">2.6 Handling and Disposal</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hematologic Effects </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Impairment of Fertility </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Teratogenesis and Mutagenesis</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Carcinogenesis</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span> </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience in Adult Patients</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trial Experience in Pediatric Patients </a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use </a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.3 Reproductive and Developmental Toxicology </a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adult Patients </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Pediatric Patients</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOXED_WARNING"></a><a name="section-1"></a><p></p>
<h1>WARNING: HEMATOLOGIC TOXICITY, CARCINOGENICITY, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">TERATOGENICITY</span>, AND<br>IMPAIRMENT OF FERTILITY</h1>
<dl>
<dt>•</dt>
<dd>Clinical toxicity of valganciclovir which is metabolized to ganciclovir includes <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> [see <span class="Bold">Warnings and Precautions <a href="#_5cd95167-f74b-ca07-7652-0134728a2dd2">(5.1)</a></span>].</dd>
<dt>•</dt>
<dd>In animal studies, ganciclovir was carcinogenic, teratogenic, and caused aspermatogenesis [see <span class="Bold">Warnings and Precautions (<a href="#_06a3bb9b-72b3-372c-7d37-5d7e4c0fb67f">5.2</a>, <a href="#_bf09797e-c0bf-46f1-6c27-2130536e9d66">5.3</a>, <a href="#_25475139-aac8-fedb-01b6-4e9931bdae5c">5.4</a>)</span>]. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INDICATIONS_AND_USAGE"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_ab954377-2249-c26e-5b9b-5de6cf7a2f8d"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Adult Patients </h2>
<p class="First">Treatment of Cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">Retinitis</span>: Valganciclovir tablets USP are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> in patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS) [see <span class="Bold">Clinical Studies <a href="#_87580389-2261-aef1-9a8b-92c42c8a3a7b"> (14.1)</a></span>]. </p>
<p>Prevention of CMV Disease: Valganciclovir tablets USP are indicated for the prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]) [see <span class="Bold">Clinical Studies <a href="#_87580389-2261-aef1-9a8b-92c42c8a3a7b">(14.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_497aa9c7-ee17-2f61-7629-34f04737f9c6"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Pediatric Patients</h2>
<p class="First">Prevention of CMV Disease: Valganciclovir tablets USP are indicated for the prevention of CMV disease in kidney or heart transplant patients (4 months to 16 years of age) at high risk [see <span class="Bold">Clinical Studies <a href="#_dd13e914-34d3-cf64-6db0-cfc621d25a2c">(14.2)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_0248e78d-f036-6a15-65db-1e52d4d3efb4"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Limitations of Use </h2>
<p class="First">Valganciclovir tablet USP is not indicated for use in either adult or pediatric liver transplant patients [see <span class="Bold">Clinical Studies (<a href="#_87580389-2261-aef1-9a8b-92c42c8a3a7b">14.1</a>, <a href="#_dd13e914-34d3-cf64-6db0-cfc621d25a2c">14.2</a>)</span>]. </p>
<p>The safety and efficacy of valganciclovir tablets USP have not been established for: </p>
<dl>
<dt>•</dt>
<dd>Prevention of CMV disease in solid organ transplants other than those indicated [see <span class="Bold">Clinical Studies</span> (<span class="Bold"><a href="#_87580389-2261-aef1-9a8b-92c42c8a3a7b">14.1</a>, <a href="#_dd13e914-34d3-cf64-6db0-cfc621d25a2c">14.2</a></span>)]. </dd>
<dt>•</dt>
<dd>Prevention of CMV disease in pediatric solid organ transplant patients &lt; 4 months of age [see <span class="Bold">Clinical Studies <a href="#_dd13e914-34d3-cf64-6db0-cfc621d25a2c">(14.2)</a></span>].</dd>
<dt>•</dt>
<dd>Treatment of congenital CMV disease [see <span class="Bold">Use in Specific Populations <a href="#_6fde80df-45f9-9142-74e7-613f8ddc8961">(8.4)</a></span>] </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DOSAGE_AND_ADMINISTRATION"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_61051f57-8ca3-f04c-82c8-4ab291b78984"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Dosing Information </h2>
<dl>
<dt>•</dt>
<dd>Valganciclovir tablets USP should be taken with food [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. </dd>
<dt>•</dt>
<dd>The bioavailability of ganciclovir from valganciclovir is significantly higher than from ganciclovir capsules. Therefore, valganciclovir tablets USP cannot be substituted for ganciclovir capsules on a one-to-one basis [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. </dd>
<dt>•</dt>
<dd>Adult patients should use valganciclovir tablets, not valganciclovir for oral solution.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_0fefa25e-de81-0837-0182-295b5bf2830e"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Adult Patients With Normal Renal Function</h2>
<p class="First">For dosage recommendations in adult patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Bold">Dosage and Administration <a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">(2.5)</a></span>]. </p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span>: Induction: </p>
<dl>
<dt>•</dt>
<dd>The recommended dose is 900 mg (two 450 mg tablets) twice a day for 21 days. </dd>
<dt>•</dt>
<dd>Maintenance: Following induction treatment, or in adult patients with inactive <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, the recommended dose is 900 mg (two 450 mg tablets) once a day. </dd>
</dl>
<p>Prevention of CMV Disease: </p>
<dl>
<dt>•</dt>
<dd>For adult patients who have received a heart or kidney-pancreas transplant, the recommended dose is 900 mg (two 450 mg tablets) once a day starting within 10 days of transplantation until 100 days post-transplantation. </dd>
<dt>•</dt>
<dd>For adult patients who have received a kidney transplant, the recommended dose is 900 mg (two 450 mg tablets) once a day starting within 10 days of transplantation until 200 days post-transplantation. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_423e083e-18b4-6f88-1e63-91d42ec55a0a"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Pediatric Patients </h2>
<p class="First">Prevention of CMV Disease: For pediatric patients 4 months to 16 years of age who have received a kidney or heart transplant, the recommended once daily dose of valganciclovir tablets USP starting within 10 days of transplantation until 100 days post-transplantation is based on body surface area (BSA) and creatinine clearance (CrCl) derived from a modified Schwartz formula, and is calculated using the equation below: </p>
<p>Pediatric Dose (mg) = 7 x BSA x CrCl (calculated using a modified Schwartz formula). If the calculated Schwartz creatinine clearance exceeds 150 mL/min/1.73m<span class="Sup">2</span>, then a maximum value of 150 mL/min/1.73m<span class="Sup">2 </span>should be used in the equation.</p>
<div class="Figure">
<a name="id523"></a><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4db6dd63-e56b-45a4-86b2-ee125a1854a0&amp;name=image-01.jpg">
</div>
<p><span class="Italics">where k =</span></p>
<p>0.45 for patients aged 4 months to &lt; 1 year, </p>
<p>0.45 for patients aged 1 to &lt; 2 years (note k value is 0.45 instead of the typical value of 0.55), </p>
<p>0.55 for boys aged 2 to &lt; 13 years and girls aged 2 to 16 years, and </p>
<p>0.7 for boys aged 13 to 16 years. </p>
<p>All calculated doses should be rounded to the nearest 25 mg increment for the actual deliverable dose. If the calculated dose exceeds 900 mg, a maximum dose of 900 mg should be administered. Valganciclovir for oral solution is the preferred formulation since it provides the ability to administer a dose calculated according to the formula above; however, valganciclovir tablets USP may be used if the calculated doses are within 10% of available tablet strength (450 mg). For example, if the calculated dose is between 405 mg and 495 mg, one 450 mg tablet may be taken. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_593abd56-3dce-ee15-d7d1-5abd414b82af"></a><a name="section-2.4"></a><p></p>
<h2>2.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">Dosage recommendations for adult patients with reduced renal function are provided in <span class="Bold">Table 1</span>. For adult patients on hemodialysis (CrCl &lt;10 mL/min), a dose recommendation for valganciclovir tablets cannot be given [see <span class="Bold">Use in Specific Populations (<a href="#GERIATRIC_USE">8.5</a>, <a href="#_f3d1b9d3-b7be-40a3-5fb1-826576d0e996">8.6</a> ), Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. </p>
<p><span class="Bold">Table 1 Dosage Recommendations for Adult Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></p>
<table cellpadding="0.4pt" cellspacing="0pt" width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Valganciclovir 450 mg Tablets</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">CrCl*(mL/min)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Induction Dose</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Maintenance/ Prevention Dose</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">≥ 60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">900 mg twice daily</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">900 mg once daily</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">40 to 59</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">450 mg twice daily</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">450 mg once daily</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">25 to 39</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">450 mg once daily</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">450 mg every 2 days</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10 to 24</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">450 mg every 2 days</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">450 mg twice weekly</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">&lt; 10 (on hemodialysis)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">not recommended</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">not recommended</p></td>
</tr>
</tbody>
</table>
<p>*An estimated creatinine clearance is calculated from serum creatinine by the following formulas: </p>
<p>For males=                              (140 – age [years]) x (body weight [kg])</p>
<p>                                                _______________________________</p>
<p>                                                   (72) x (serum creatinine [mg/dL])</p>
<p>For females= 0.85 x male value</p>
<p>Dosing in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> can be done using the recommended equations because CrCl is a component in the calculation [see <span class="Bold">Dosage and Administration <a href="#_423e083e-18b4-6f88-1e63-91d42ec55a0a">(2.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_ec90ff32-b383-1436-9a6c-397a64a00482"></a><a name="section-2.5"></a><p></p>
<h2>2.6 Handling and Disposal</h2>
<p class="First">Caution should be exercised in the handling of valganciclovir tablets USP. Tablets should not be broken or crushed. Because valganciclovir is considered a potential teratogen and carcinogen in humans, caution should be observed in handling broken tablets, [see <span class="Bold">Warnings and Precautions (<a href="#_bf09797e-c0bf-46f1-6c27-2130536e9d66">5.3</a>, <a href="#_25475139-aac8-fedb-01b6-4e9931bdae5c">5.4</a>)</span>]. Avoid direct contact with broken or crushed tablets with skin or mucous membranes. If such contact occurs, wash thoroughly with soap and water, and rinse eyes thoroughly with plain water.</p>
<p>Because ganciclovir shares some of the properties of antitumor agents (i.e., carcinogenicity and mutagenicity), consideration should be given to handling and disposal according to guidelines issued for antineoplastic drugs. Several guidelines on this subject have been published. However, there is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate [see <span class="Bold">References <a href="#REFERENCES">(15)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="DOSAGE_FORMS_AND_STRENGTHS"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Valganciclovir Tablets:</p>
<dl>
<dt>•</dt>
<dd>450 mg are pink colored, oval shaped, film coated tablets debossed with ‘RDY’ on one side and ‘762’ on other side. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Valganciclovir is contraindicated in patients who have had a demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to valganciclovir, ganciclovir, or any component of the formulation [see <span class="Bold">Adverse Reactions <a href="#_0e93312a-51dd-d412-21f8-b0edc769c1e1">(6.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="WARNINGS_AND_PRECAUTIONS"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_5cd95167-f74b-ca07-7652-0134728a2dd2"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Hematologic Effects </h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, bone marrow <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported in patients treated with valganciclovir or ganciclovir. <span class="Bold">Valganciclovir should not be administered if the absolute neutrophil count is less than 500 cells/μL, the platelet count is less than 25,000/μL, or the hemoglobin is less than 8 g/dL. </span>Valganciclovir should also be used with caution in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span>, or who have received or who are receiving myelosuppressive drugs or irradiation. <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">Cytopenia</span> may occur at any time during treatment and may worsen with continued dosing. Cell counts usually begin to recover within 3 to 7 days after discontinuing drug. </p>
<p>Due to the frequency of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in patients receiving valganciclovir [see <span class="Bold">Adverse Reactions (<a href="#_0e93312a-51dd-d412-21f8-b0edc769c1e1">6.1</a>, <a href="#_28a725fb-a1ac-9c41-06f1-2b3b548ee593">6.2</a>)</span>], complete blood counts with differential and platelet counts should be performed frequently, especially in patients in whom ganciclovir or other nucleoside analogues have previously resulted in <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, or in whom neutrophil counts are less than 1000 cells/μL at the beginning of treatment. Increased monitoring for <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenias</span> may be warranted if therapy with oral ganciclovir is changed to valganciclovir , because of increased plasma concentrations of ganciclovir after valganciclovir  administration [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_06a3bb9b-72b3-372c-7d37-5d7e4c0fb67f"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Impairment of Fertility </h2>
<p class="First">Animal data indicate administration of ganciclovir causes inhibition of spermatogenesis and subsequent <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>. These effects were reversible at lower doses but irreversible at higher doses [see <span class="Bold">Nonclinical Toxicology <a href="#CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">(13.1)</a></span>]. In men, valganciclovir at the recommended doses may cause temporary or permanent inhibition of spermatogenesis. Animal data also indicate suppression of fertility in females may occur. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_bf09797e-c0bf-46f1-6c27-2130536e9d66"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Teratogenesis and Mutagenesis</h2>
<p class="First">Animal data indicate ganciclovir is teratogenic and mutagenic. Therefore, valganciclovir should be considered to have the potential to cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> and cancers in humans. Women of childbearing potential should be advised to use effective contraception during treatment and for at least 30 days following treatment with valganciclovir. Similarly, men should be advised to practice barrier contraception during and for at least 90 days following treatment with valganciclovir [see <span class="Bold">Dosage and Administration <a href="#_ec90ff32-b383-1436-9a6c-397a64a00482">(2.6)</a>, Use in Specific Populations <a href="#PREGNANCY">(8.1)</a>, Nonclinical Toxicology (<a href="#CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">13.1</a>, <a href="#_d2d681ae-b4ae-5778-9c6f-af22611a78d7">13.3</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_25475139-aac8-fedb-01b6-4e9931bdae5c"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Carcinogenesis</h2>
<p class="First">Animal data indicate that administration of ganciclovir is carcinogenic. Valganciclovir should therefore be considered a potential carcinogen in humans [see <span class="Bold">Dosage and Administration (<a href="#_ec90ff32-b383-1436-9a6c-397a64a00482">2.6</a>), Nonclinical Toxicology (<a href="#CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY">13.1</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_596b1619-3216-1d4a-b463-3bab59bc7cf2"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute Renal Failure</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> may occur in: </p>
<dl>
<dt>•</dt>
<dd>Elderly patients with or without reduced renal function. Caution should be exercised when administering valganciclovir to geriatric patients, and dosage reduction is recommended for those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> [see <span class="Bold">Dosage and Administration <a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">(2.5)</a>, Use in Specific Populations (<a href="#GERIATRIC_USE">8.5</a>, <a href="#_f3d1b9d3-b7be-40a3-5fb1-826576d0e996">8.6</a>)</span>]. </dd>
<dt>•</dt>
<dd>Patients receiving potential nephrotoxic drugs. Caution should be exercised when administering valganciclovir to patients receiving potential nephrotoxic drugs. </dd>
<dt>•</dt>
<dd>Patients without adequate hydration. Adequate hydration should be maintained for all patients. </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ADVERSE_REACTIONS"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse events are discussed in greater detail in other sections of the labeling: </p>
<dl>
<dt>•</dt>
<dd>Hematologic adverse events [see <span class="Bold">Boxed Warning, Warnings and Precautions <a href="#_5cd95167-f74b-ca07-7652-0134728a2dd2">(5.1)</a></span>] </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">Acute renal failure</span> [see <span class="Bold">Warnings and Precautions <a href="#_596b1619-3216-1d4a-b463-3bab59bc7cf2">(5.5)</a></span>]  </dd>
</dl>
<p>The most common adverse events and laboratory abnormalities reported in at least one indication by ≥ 20% of adult patients treated with valganciclovir tablets are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">graft rejection</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The most common reported adverse events and laboratory abnormalities reported in &gt; 10% of pediatric solid organ transplant recipients treated with valganciclovir tablets are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.   </p>
<div class="Section" data-sectionCode="42229-5">
<a name="_0e93312a-51dd-d412-21f8-b0edc769c1e1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience in Adult Patients</h2>
<p class="First">Valganciclovir, a prodrug of ganciclovir, is rapidly converted to ganciclovir after oral administration. Adverse events known to be associated with ganciclovir usage can therefore be expected to occur with valganciclovir. </p>
<p>Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect rates observed in practice. </p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span> in AIDS Patients: In a clinical study for the treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> in HIV-infected patients, the adverse events reported by patients receiving valganciclovir tablets (n=79) or intravenous ganciclovir (n=79) for 28 days of randomized therapy (21 days induction dose and 7 days maintenance dose), respectively, included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (16%, 10%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (8%, 14%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (9%, 5%), and catheter-related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (3%, 11%). The incidence of adverse events was similar between the group who received valganciclovir tablets and the group who received intravenous ganciclovir, with the exception of catheter-related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, which occurred with greater frequency in patients randomized to receive intravenous ganciclovir. The frequencies of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (ANC &lt; 500/μL) were 11% for patients receiving valganciclovir tablets compared with 13% for patients receiving intravenous ganciclovir. <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (Hgb &lt; 8 g/dL) occurred in 8% of patients in each group. Other laboratory abnormalities occurred with similar frequencies in the two groups. </p>
<p>Adverse events and abnormal laboratory values data are available for 370 patients who received maintenance therapy with valganciclovir tablets 900 mg once daily in two open-label clinical trials. Approximately 252 (68%) of these patients received valganciclovir tablets for more than nine months (maximum duration was 36 months). <span class="Bold">Table 2 </span>and <span class="Bold">Table 3 </span>show the pooled adverse event data and abnormal laboratory values from these patients. </p>
<p><span class="Bold">Table 2 Pooled Selected Adverse Events Reported in </span>≥ <span class="Bold">5% of Patients who Received Valganciclovir Tablets Maintenance Therapy for <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span></span></p>
<table cellpadding="0.4pt" cellspacing="0pt" width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Adverse Events According to Body System</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets</span><br><span class="Bold">(N=370)</span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Gastrointestinal system </span><br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> <br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> <br><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> <br><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>41<br>30<br>21<br>15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Body as a whole </span><br><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> <br><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">31<br>22</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Central and peripheral nervous system </span><br><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> <br><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> <br><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>16<br>9<br>8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Special senses </span><br><span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">Retinal detachment</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>15</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Table 3 Pooled Laboratory Abnormalities Reported in Patients Who Received Valganciclovir Tablets Maintenance Therapy for the Treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span></span></p>
<table cellpadding="0.4pt" cellspacing="0pt" width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Laboratory Abnormalities</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets </span><br><span class="Bold">(N=370) </span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: ANC/μL <br>&lt; 500 <br>500  to &lt; 750 <br>750  to &lt; 1000 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">19<br>17<br>17</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>: Hemoglobin g/dL <br>&lt; 6.5 <br>6.5  to &lt; 8.0 <br>8.0  to &lt; 9.5 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">7<br>13<br>16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>: Platelets/μL <br>&lt; 25000 <br>25000  to &lt; 50000 <br>50000 to &lt; 100000 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4<br>6<br>22</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Serum Creatinine: mg/dL <br>&gt; 2.5 <br>&gt; 1.5  to 2.5 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3<br>12</p></td>
</tr>
</tbody>
</table>
<p>Prevention of CMV Disease in Selected Solid Organ Transplantation:<span class="Bold"> Table 4 </span>shows selected adverse events regardless of severity and drug relationship with an incidence of ≥ 5% from a clinical trial (up to 28 days after study treatment) where heart, kidney, kidney-pancreas and liver transplant patients received valganciclovir tablets (N=244) or oral ganciclovir (N=126) until Day 100 post-transplant. The majority of the adverse events were of mild or moderate intensity. </p>
<p><span class="Bold">Table 4 Percentage of Selected Grades 1 to 4 Adverse Events Reported in </span>≥ <span class="Bold">5% of Patients From a Study of Selected Solid Organ Transplant Patients </span></p>
<table cellpadding="0.3pt" cellspacing="0pt" width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets </span><br><span class="Bold">(N=244) </span><br><span class="Bold">%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Oral Ganciclovir</span><br><span class="Bold">(N=126) </span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">29</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremors</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">28</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">Graft rejection</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">24</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">30</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">23</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">23</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">27</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14</p></td>
</tr>
</tbody>
</table>
<p>The overall safety profile of valganciclovir did not change with the extension of prophylaxis until Day 200 post-transplant in high risk kidney transplant patients (see <span class="Bold">Table 5</span>).  </p>
<p><span class="Bold">Table 5 Percentage of Selected Grades 1-4 Adverse Events Reported in </span>≥ <span class="Bold">5% of Patients from a Study of Kidney Transplant Patients</span></p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Adverse Event</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets </span><br><span class="Bold">Day 100 Post-transplant</span><br><span class="Bold">(N=164)</span><br><span class="Bold">%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets </span><br><span class="Bold">Day 200 Post-transplant</span><br><span class="Bold">(N=156)</span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">31</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremors</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">17</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">13</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">Transplant rejection</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
</tr>
</tbody>
</table>
<p>Adverse events not included in <span class="Bold">Table 4 and Table 5</span>, which either occurred at a frequency of ≥ 5% in clinical studies with solid organ transplant patients, or were selected serious adverse events reported in studies with patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> or in studies with solid organ transplant patients with a frequency of &lt; 5% are listed below. </p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>: valganciclovir <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>  </p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> complications: potentially life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>  </p>
<p>Central and peripheral nervous system: <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (excluding <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>  </p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>  </p>
<p>General disorders and administration site disorders: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>  </p>
<p>Hemic system: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>  </p>
<p>Hepatobiliary disorders: abnormal hepatic function  </p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>: <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, local and systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="4237450" conceptname="Postoperative wound infection">postoperative wound infection</span>  </p>
<p>Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, and procedural complications: postoperative complications, <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span>, increased <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> drainage, <span class="product-label-link" type="condition" conceptid="439981" conceptname="Wound dehiscence">wound dehiscence</span>  </p>
<p>Metabolism and nutrition disorders: <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite decreased</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>  </p>
<p>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>: <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, limb pain </p>
<p>Psychiatric disorders: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>  </p>
<p>Renal and urinary disorders: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, decreased creatinine clearance  </p>
<p>Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>: <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>  </p>
<p>Skin and subcutaneous tissue disorders: <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>  </p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> </p>
<p>Laboratory abnormalities reported with valganciclovir tablets in two studies in solid organ transplant patients are listed in <span class="Bold">Table 6 and Table 7</span>. </p>
<p><span class="Bold">Table 6 Laboratory Abnormalities Reported in a Study of Selected Solid Organ Transplant Patients* </span></p>
<table cellpadding="0.3pt" cellspacing="0pt" width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Laboratory Abnormalities</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets</span><br><span class="Bold"> (N=244) </span><br><span class="Bold">%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Ganciclovir Capsules</span><br><span class="Bold">(N=126) </span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: ANC/μL <br>&lt; 500 <br>500 to &lt; 750 <br>750  to &lt; 1000 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>5<br>3<br>5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>3<br>2<br>2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>: Hemoglobin g/dL <br>&lt; 6.5 <br>6.5 to &lt; 8.0 <br>8.0 to &lt; 9.5 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>1<br>5<br>31</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>2<br>7<br>25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>: Platelets/μL <br>&lt; 25000 <br>25000 to &lt; 50000 <br>50000 to &lt; 100000 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>0<br>1<br>18</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>2<br>3<br>21</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Serum Creatinine: mg/dL <br>&gt; 2.5 <br>&gt; 1.5  to 2.5 </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>14<br>45</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>21<br>47</p></td>
</tr>
</tbody>
</table>
<p>*Laboratory abnormalities are those reported by investigators.</p>
<p><span class="Bold">Table 7 Laboratory Abnormalities Reported in a Study of Kidney Transplant Patients* </span></p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Laboratory Abnormalities</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets</span><br><span class="Bold"> Day 100 Post-transplant</span><br><span class="Bold">(N=164)</span><br><span class="Bold">%</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets</span><br><span class="Bold">Day 200 Post-transplant</span><br><span class="Bold">(N=156)</span><br><span class="Bold">%</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>: ANC/μL</p>
<p>&lt; 500</p>
<p>500 – &lt; 750</p>
<p>750 – &lt; 1000</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">9</p>
<p>6</p>
<p>7</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">10</p>
<p>6</p>
<p>5</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>: Hemoglobin g/dL</p>
<p>&lt; 6.5</p>
<p>6.5 – &lt; 8.0</p>
<p>8.0 – &lt; 9.5</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">0</p>
<p>5</p>
<p>17</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">1</p>
<p>1</p>
<p>15</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>: Platelets/μL</p>
<p>&lt; 25000</p>
<p>25000 – &lt; 50000</p>
<p>50000 – &lt; 100000</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">0</p>
<p>1</p>
<p>7</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">0</p>
<p>0</p>
<p>3</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Serum Creatinine: mg/dL<br>&gt; 2.5<br>&gt; 1.5 – 2.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><br>17<br>50</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><br>14<br>48</p></td>
</tr>
</tbody>
</table>
<p>*Laboratory abnormalities are those reported by investigators.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_28a725fb-a1ac-9c41-06f1-2b3b548ee593"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trial Experience in Pediatric Patients </h2>
<p class="First">Valganciclovir for oral solution and tablets have been studied in 109 pediatric solid organ transplant patients who were at risk for developing CMV disease (aged 4 months to 16 years) and in 24 neonates with symptomatic congenital CMV disease (aged 8 to 34 days), with duration of ganciclovir exposure ranging from 2 to 100 days. <br>The overall safety profile was similar in pediatric patients as compared to adult patients. However, the rates of certain adverse events and laboratory abnormalities, such as <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, were reported more frequently in pediatric patients than in adults [see <span class="Bold">Use in Specific Populations (<a href="#_6fde80df-45f9-9142-74e7-613f8ddc8961">8.4</a>), Clinical Studies (<a href="#_dd13e914-34d3-cf64-6db0-cfc621d25a2c">14.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_51f50553-fa67-cfbf-26a8-047b589b547e"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">In general, the adverse events reported during the postmarketing use of valganciclovir were similar to those identified during the clinical trials and to those reported during the postmarketing use of ganciclovir. Please also refer to the intravenous ganciclovir product information and ganciclovir capsule product information for more information on postmarketing adverse events associated with ganciclovir. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DRUG_INTERACTIONS"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">In vivo</span> drug-drug interaction studies were not conducted with valganciclovir. However, because valganciclovir is rapidly and extensively converted to ganciclovir, drug-drug interactions associated with ganciclovir will be expected for valganciclovir. Established and other potentially significant drug interactions conducted with ganciclovir are listed in <span class="Bold">Table 8</span>.</p>
<p><span class="Bold">Table 8 Established and Other Potentially Significant Drug Interactions With Ganciclovir</span></p>
<table cellpadding="0.3pt" cellspacing="0pt" width="100%">
<col width="31%">
<col width="33%">
<col width="36%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Name of the Concomitant <br>Drug</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Change in the Concentration of Ganciclovir or Concomitant Drug</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Clinical Comment</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Zidovudine </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">↓ Ganciclovir <br>↑ Zidovudine </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Zidovudine and valganciclovir  each have the potential to cause <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Probenecid </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">↑ Ganciclovir </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Patients taking probenecid and valganciclovir  should be monitored for evidence of ganciclovir toxicity </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Mycophenolate Mofetil (MMF) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">↔ Ganciclovir (in patients with normal renal function) <br>↔ MMF (in patients with normal renal function) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be monitored carefully as levels of MMF metabolites and ganciclovir may increase </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Didanosine </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">↓ Ganciclovir <br>↑ Didanosine </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Patients should be closely monitored for didanosine toxicity </p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="USE_IN_SPECIFIC_POPULATIONS"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="PREGNANCY"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Teratogenic Effects: Pregnancy Category C After oral administration, valganciclovir (prodrug) is converted to ganciclovir (active drug) and, therefore, is expected to have reproductive toxicity effects similar to ganciclovir. There are no adequate and well-controlled studies of valganciclovir or ganciclovir use in pregnant women. In animal studies of ganciclovir, embryo-fetal toxicity and structural malformations occurred. Valganciclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p>In animal studies, pregnant mice and rabbits received ganciclovir at doses that produced 2x the human exposure (based on AUC comparison). Treated rabbits had increased rates of fetal resorption, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span>, embryolethality, maternal toxicity, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>/<span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, aplastic organs (kidney and pancreas), <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span> and brachygnathia. In mice, increased fetal resorptions and embryolethality occurred in the presence of maternal/fetal toxicity. </p>
<p>Daily intravenous doses of approximately 1.7x the human exposure (based on AUC) administered to female mice prior to mating, during gestation, and during lactation caused hypoplasia of the testes and seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> in month-old male offspring, as well as pathologic changes in the nonglandular region of the stomach. </p>
<p>Data from an <span class="Italics">ex vivo</span> human placental model showed that ganciclovir crosses the human placenta. The transfer occurred by passive diffusion and was not saturable over a concentration range of 1 to 10 mg/mL [see <span class="Bold">Nonclinical Toxicology <a href="#_d2d681ae-b4ae-5778-9c6f-af22611a78d7">(13.3)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="NURSING_MOTHERS"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether valganciclovir (prodrug) or ganciclovir (active drug) are excreted in human milk. Because valganciclovir caused <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> in clinical trials and ganciclovir was mutagenic and carcinogenic in animal studies, serious adverse events may occur from ganciclovir exposure in nursing infants [see <span class="Bold"><a href="#_RefBOXED_WARNING">Boxed Warning</a>, Warnings and Precautions (<a href="#_5cd95167-f74b-ca07-7652-0134728a2dd2">5.1</a>, <a href="#_bf09797e-c0bf-46f1-6c27-2130536e9d66">5.3</a>, <a href="#_25475139-aac8-fedb-01b6-4e9931bdae5c">5.4</a>)</span>]. Because of the potential for serious adverse events in nursing infants, a decision should be made whether to discontinue nursing or discontinue drug, taking into consideration the importance of the drug to the mother. The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_6fde80df-45f9-9142-74e7-613f8ddc8961"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use </h2>
<p class="First">Valganciclovir for oral solution and tablets are indicated for the prevention of CMV disease in kidney or heart transplant pediatric patients 4 months to 16 years of age at risk for developing CMV disease [see <span class="Bold">Indications and Usage <a href="#_497aa9c7-ee17-2f61-7629-34f04737f9c6">(1.2)</a>, Dosage and Administration <a href="#_423e083e-18b4-6f88-1e63-91d42ec55a0a">(2.3)</a></span>]. </p>
<p>The use of valganciclovir for oral solution and tablets for the prevention of CMV disease in pediatric patients 4 months to 16 years of age with kidney or heart transplant is based on pharmacokinetic, safety, and efficacy data from an open-label trial with oral valganciclovir (valganciclovir for oral solution or tablets) in pediatric solid organ transplant recipients at risk for developing CMV disease. The results of this study were supported by previous demonstration of efficacy in adult patients [see <span class="Bold">Adverse Reactions <a href="#_28a725fb-a1ac-9c41-06f1-2b3b548ee593">(6.2)</a>, Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a>, Clinical Studies <a href="#_dd13e914-34d3-cf64-6db0-cfc621d25a2c">(14.2)</a></span>]. </p>
<p>The safety and efficacy of valganciclovir for oral solution and tablets have not been established in children for: </p>
<dl>
<dt>•</dt>
<dd>Prevention of CMV disease in liver transplant patients </dd>
<dt>•</dt>
<dd>Prevention of CMV disease in solid organ transplants other than those indicated </dd>
<dt>•</dt>
<dd>Prevention of CMV disease in pediatric solid organ transplant patients &lt; 4 months of age </dd>
<dt>•</dt>
<dd>Treatment of congenital CMV disease </dd>
</dl>
<p>The pharmacokinetic profile and safety of valganciclovir for oral solution in children were studied in two open-label studies. </p>
<p>Study 1 was an open-label trial with oral valganciclovir (valganciclovir for oral solution or tablets) in pediatric solid organ transplant recipients at risk for developing CMV disease [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a>, Clinical Studies <a href="#_dd13e914-34d3-cf64-6db0-cfc621d25a2c">(14.2)</a></span>]. </p>
<p>Study 2 was a pharmacokinetic and pharmacodynamic evaluation of valganciclovir for oral solution in neonates with <span class="product-label-link" type="condition" conceptid="436532" conceptname="Congenital cytomegalovirus infection">congenital CMV infection</span> involving the central nervous system. Twenty-four neonates were enrolled in this study. All patients were treated for 6 weeks with a combination of intravenous ganciclovir 6 mg/kg twice daily and valganciclovir for oral solution at doses ranging from 14 mg/kg to 20 mg/kg twice daily. The pharmacokinetic results showed that in infants &gt; 7 days to 3 months of age, a dose of 16 mg/kg twice daily of valganciclovir for oral solution provided ganciclovir systemic exposures (median AUC<span class="Sub">0-12h</span> = 23.6 [range 16.8 – 35.5] μg<span class="Bold">·</span>h/mL; n = 6) comparable to those obtained in infants up to 3 months from a 6 mg/kg dose of intravenous ganciclovir twice daily (AUC<span class="Sub">0-12h</span> = 25.3 [range 2.4 – 89.7] μg<span class="Bold">·</span>h/mL; n = 18) or to the ganciclovir systemic exposures obtained in adults from a 900 mg dose of valganciclovir tablets twice daily.</p>
<p>The safety and efficacy of intravenous ganciclovir have not been established for the treatment of <span class="product-label-link" type="condition" conceptid="436532" conceptname="Congenital cytomegalovirus infection">congenital CMV infection</span> in infants and no similar disease occurs in adults; therefore, efficacy cannot be extrapolated from intravenous ganciclovir use in adults. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="GERIATRIC_USE"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Studies of valganciclovir tablets have not been conducted in adults older than 65 years of age. Clinical studies of valganciclovir did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Valganciclovir is known to be substantially excreted by the kidneys, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. In addition, renal function should be monitored and dosage adjustments should be made accordingly [see <span class="Bold">Dosage and Administration <a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">(2.5)</a>, Warnings and Precautions <a href="#_596b1619-3216-1d4a-b463-3bab59bc7cf2">(5.5)</a>, Use in Specific Populations <a href="#_f3d1b9d3-b7be-40a3-5fb1-826576d0e996">(8.6)</a>, Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_f3d1b9d3-b7be-40a3-5fb1-826576d0e996"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </h2>
<p class="First">Dose reduction is recommended when administering valganciclovir  to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Bold">Dosageand Administration <a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">(2.5)</a>, Warnings and Precautions <a href="#_596b1619-3216-1d4a-b463-3bab59bc7cf2">(5.5)</a>, Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. </p>
<p>For adult patients on hemodialysis (CrCl &lt;10 mL/min) valganciclovir tablets should not be used. Adult hemodialysis patients should use ganciclovir in accordance with the dose-reduction algorithm cited in the Cytovene<span class="Sup">®</span> -IV and ganciclovir capsules complete product information section on DOSAGE AND ADMINISTRATION: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> [see <span class="Bold">Dosage and Administration <a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">(2.5)</a> and Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_bc182bd3-f15f-6841-8db7-2e93a85df2bb"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The safety and efficacy of valganciclovir have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="OVERDOSAGE"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Experience with Valganciclovir Tablets: One adult developed fatal <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> (medullary <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>) after several days of dosing that was at least 10-fold greater than recommended for the patient’s estimated degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
<p>An <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of valganciclovir could also possibly result in increased renal toxicity [see <span class="Bold">Dosage and Administration <a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">(2.5)</a>, Use in Specific Populations <a href="#_f3d1b9d3-b7be-40a3-5fb1-826576d0e996">(8.6)</a></span>]. </p>
<p>Because ganciclovir is dialyzable, dialysis may be useful in reducing serum concentrations in patients who have received an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of valganciclovir [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. Adequate hydration should be maintained. The use of hematopoietic growth factors should be considered [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. </p>
<p><span class="Italics">Experience with Intravenous Ganciclovir</span>: Reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> with intravenous ganciclovir have been received from clinical trials and during postmarketing experience. The majority of patients experienced one or more of the following adverse events: </p>
<p><span class="Italics">Hematological toxicity:</span> <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, medullary <span class="product-label-link" type="condition" conceptid="4166825" conceptname="Aplasia">aplasia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> </p>
<p><span class="Italics">Hepatotoxicity:</span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, liver function disorder </p>
<p><span class="Italics">Renal toxicity:</span> worsening of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> in a patient with pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, elevated creatinine </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">Gastrointestinal toxicity</span>:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">Neurotoxicity</span>:</span> generalized <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span> </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="DESCRIPTION"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Valganciclovir hydrochloride USP, a hydrochloride salt of the L-valyl ester of ganciclovir that exists as a mixture of two diastereomers. Ganciclovir is a synthetic guanine derivative active against CMV. </p>
<p>Valganciclovir hydrochloride USP is available as a 450 mg tablet for oral administration. Each tablet contains 496.3 mg of valganciclovir hydrochloride USP (corresponding to 450 mg of valganciclovir), and the inactive ingredients crospovidone, magnesium stearate, microcrystalline cellulose and povidone. The film-coat applied to the tablets contains hypromellose, iron oxide red, polyethylene glycol, polysorbate and titanium dioxide.</p>
<p>Valganciclovir hydrochloride USP is a white to almost white powder with a molecular formula of C<span class="Sub">14</span>H<span class="Sub">22</span>N<span class="Sub">6</span>O<span class="Sub">5</span>·HCl and a molecular weight of 390.71. The chemical name for valganciclovir hydrochloride USP is L-Valine, 2[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester, monohydrochloride. Valganciclovir hydrochloride USP is a polar hydrophilic compound with a saturation solubility of 6029 mg/mL in water at 25°C and an n-octanol/water partition coefficient of 0.00701 at pH 5.1. The pKa for valganciclovir hydrochloride USP is 7.2. </p>
<p>The chemical structure of valganciclovir hydrochloride USP is:</p>
<div class="Figure">
<a name="id1438"></a><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4db6dd63-e56b-45a4-86b2-ee125a1854a0&amp;name=structure.jpg">
</div>
<p>All doses in this insert are specified in terms of valganciclovir. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CLINICAL_PHARMACOLOGY"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="MECHANISM_OF_ACTION"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Valganciclovir is an antiviral drug [see <span class="Bold">Microbiology <a href="#_845af12b-4be2-e876-d9ca-5d9b616564c4">(12.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="PHARMACOKINETICS"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Because the major elimination pathway for ganciclovir is renal, dosage reductions according to creatinine clearance are required for valganciclovir tablets [see <span class="Bold">Dosage and Administration <a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">(2.5)</a></span>]. </p>
<p>Pharmacokinetics in Adults: </p>
<p>The pharmacokinetics of valganciclovir and ganciclovir after administration of valganciclovir tablets have been evaluated in HIV- and CMV-seropositive patients, patients with AIDS and <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, and in solid organ transplant patients. </p>
<p>The ganciclovir pharmacokinetic parameters following administration of 900 mg valganciclovir tablets and 5 mg/kg intravenous ganciclovir and 1000 mg three times daily oral ganciclovir in HIV-positive/CMV-positive patients are summarized in <span class="Bold">Table 9</span>. </p>
<p><span class="Bold">Table 9 Mean Ganciclovir Pharmacokinetic* Measures in Healthy Volunteers and HIV-positive/CMV-positive Adults at Maintenance Dosage</span></p>
<table cellpadding="0.3pt" cellspacing="0pt" width="100%">
<col width="24%">
<col width="24%">
<col width="24%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Formulation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Intravenous Ganciclovir</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Ganciclovir Capsules</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Dosage </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">900 mg once daily with food </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5 mg/kg once daily </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1000 mg three times daily with food</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">AUC<span class="Sub">0-24h</span> (mcg<span class="Bold">·</span>h/mL) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">29.1 ± 9.7 <br>(3 studies, n=57) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">26.5 ± 5.9 <br>(4 studies, n=68) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Range of means 12.3 to 19.2 <br>(6 studies, n=94) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">C<span class="Sub">max</span> (mcg/mL) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">5.61 ± 1.52 <br>(3 studies, n=58) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">9.46 ± 2.02 <br>(4 studies, n=68) <span class="Bold"><br></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Range of means 0.955 to 1.40 <br>(6 studies, n=94) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Absolute oral bioavailability (%) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">59.4 ± 6.1 <br>(2 studies, n=32) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Not Applicable </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Range of means 6.22 ± 1.29 to 8.53 ± 1.53 (2 studies, n=32) </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Elimination half-life (hr) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">4.08 ± 0.76 <br>(4 studies, n=73) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.81 ± 0.71 <br>(4 studies, n=69) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Range of means 3.86 to 5.03 <br>(4 studies, n=61) </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Renal clearance (mL/min/kg) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">3.21 ± 0.75 <br>(1 study, n=20) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2.99 ± 0.67 <br>(1 study, n=16) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Range of means 2.67 to 3.98 <br>(3 studies, n=30) </p></td>
</tr>
</tbody>
</table>
<p>*Data were obtained from single and multiple dose studies in healthy volunteers, HIV-positive patients, and HIV-positive/CMV-positive patients with and without <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span>. Patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> tended to have higher ganciclovir plasma concentrations than patients without <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>.</p>
<p>The area under the plasma concentration-time curve (AUC) of ganciclovir administered as valganciclovir tablets (900 mg once daily) is comparable to the AUC of ganciclovir after administration of intravenous ganciclovir (5 mg/kg once daily). The C<span class="Sub">max</span> of ganciclovir following valganciclovir administration is 40% lower than the C<span class="Sub">max</span> following intravenous ganciclovir administration. During maintenance dosing, ganciclovir AUC<span class="Sub">0-24h</span> and C<span class="Sub">max</span> following oral ganciclovir administration (1000 mg three times daily) are lower relative to valganciclovir and intravenous ganciclovir. The ganciclovir C<span class="Sub">min</span> following intravenous ganciclovir and valganciclovir administration are less than the ganciclovir C<span class="Sub">min</span> following oral ganciclovir administration. The clinical significance of the differences in ganciclovir pharmacokinetics after administration of valganciclovir tablets, ganciclovir capsules, and intravenous ganciclovir is unknown. </p>
<p><span class="Bold">Figure 1 Ganciclovir Plasma Concentration Time Profiles in HIV-positive/CMV-positive Patients*</span></p>
<div class="Figure">
<a name="id1547"></a><img alt="figure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4db6dd63-e56b-45a4-86b2-ee125a1854a0&amp;name=figure1.jpg">
</div>
<p>*Plasma concentration-time profiles for ganciclovir (GCV) from valganciclovir (VGCV) and intravenous ganciclovir were obtained from a multiple dose study (n=21 and n=18, respectively) in HIV-positive/CMV-positive patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. The plasma concentration-time profile for oral ganciclovir was obtained from a multiple dose study (n=24) in HIV-positive/CMV-positive patients without <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. </p>
<p>In solid organ transplant recipients, the mean systemic exposure to ganciclovir was 1.7x higher following administration of 900 mg valganciclovir tablets once daily versus 1000 mg ganciclovir capsules three times daily, when both drugs were administered according to their renal function dosing algorithms. The systemic ganciclovir exposures attained were comparable across kidney, heart and liver transplant recipients based on a population pharmacokinetics evaluation (see <span class="Bold">Table 10</span>).</p>
<p><span class="Bold">Table 10 Mean Ganciclovir Pharmacokinetic Measures by Organ Transplant Type</span></p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Ganciclovir Capsules</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Dosage </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1000 mg three times daily with food</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">900 mg once daily with food</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Heart Transplant Recipients </span><br>AUC<span class="Sub">0-24h</span> (mcg<span class="Bold">·</span>h/mL) <br>C<span class="Sub">max</span> (mcg/mL) <br>Elimination half-life (hr) </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N=13 <br><br>26.6 ± 11.6 <br>1.4 ± 0.5 <br>8.47 ± 2.84</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N=17<br><br>40.2 ± 11.8 <br>4.9 ± 1.1 <br>6.58 ± 1.50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Liver Transplant Recipients </span><br>AUC<span class="Sub">0-24h</span> (mcg<span class="Bold">·</span>h/mL) <br>C<span class="Sub">max</span> (mcg/mL) <br>Elimination half-life (hr) </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N=33<br><br>24.9 ± 10.2 <br>1.3 ± 0.4 <br>7.68 ± 2.74</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N=75<br><br>46.0 ± 16.1 <br>5.4 ± 1.5 <br>6.18 ± 1.42</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Kidney Transplant Recipients* </span><br>AUC<span class="Sub">0-24h</span> (μg<span class="Bold">·</span>h/mL) <br>C<span class="Sub">max</span> (μg/mL) <br>Elimination half-life (hr) </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N=36<br><br>31.3 ± 10.3 <br>1.5 ± 0.5 <br>9.44 ± 4.37</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N=68<br><br>48.2 ± 14.6 <br>5.3 ± 1.5 <br>6.77 ± 1.25</p></td>
</tr>
</tbody>
</table>
<p>* Includes kidney-pancreas </p>
<p>The pharmacokinetic parameters of ganciclovir following 200 days of valganciclovir administration in high-risk kidney transplant patients were similar to those previously reported in solid organ transplant patients who received valganciclovir for 100 days. </p>
<p>In a pharmacokinetic study in liver transplant patients, the ganciclovir AUC<span class="Sub">0-24h</span> achieved with 900 mg valganciclovir was 41.7 ± 9.9 mcg<span class="Bold">·</span>h/mL (n=28) and the AUC<span class="Sub">0-24h</span> achieved with the approved dosage of 5 mg/kg intravenous ganciclovir was 48.2 ± 17.3 mcg<span class="Bold">·</span>h/mL (n=27). </p>
<p><span class="Italics">Absorption: </span>Valganciclovir, a prodrug of ganciclovir, is well absorbed from the gastrointestinal tract and rapidly metabolized in the intestinal wall and liver to ganciclovir. The absolute bioavailability of ganciclovir from valganciclovir tablets following administration with food was approximately 60% (3 studies, n=18; n=16; n=28). </p>
<p>Ganciclovir median T<span class="Sub">max</span> following administration of 450 mg to 2625 mg valganciclovir tablets ranged from 1 to 3 hours. Dose proportionality with respect to ganciclovir AUC following administration of valganciclovir tablets was demonstrated only under fed conditions. Systemic exposure to the prodrug, valganciclovir, is transient and low, and the AUC<span class="Sub">24</span> and C<span class="Sub">max</span> values are approximately 1% and 3% of those of ganciclovir, respectively. </p>
<p><span class="Italics">Food Effects: </span>When valganciclovir tablets were administered with a high fat meal containing approximately 600 total calories (31.1 g fat, 51.6 g carbohydrates and 22.2 g protein) at a dose of 875 mg once daily to 16 HIV-positive subjects, the steady-state ganciclovir AUC increased by 30% (95% CI 12% to 51%), and the C<span class="Sub">max</span> increased by 14% (95% CI -5% to 36%), without any prolongation in time to peak plasma concentrations (T<span class="Sub">max</span>). Valganciclovir should be administered with food [see <span class="Bold">Dosage and Administration <a href="#_61051f57-8ca3-f04c-82c8-4ab291b78984">(2.1)</a></span>]. </p>
<p><span class="Italics">Distribution: </span>Due to the rapid conversion of valganciclovir to ganciclovir, plasma protein binding of valganciclovir was not determined. Plasma protein binding of ganciclovir is 1% to 2% over concentrations of 0.5 and 51 mcg/mL. When ganciclovir was administered intravenously, the steady-state volume of distribution of ganciclovir was 0.703 ± 0.134 L/kg (n=69). </p>
<p>After administration of valganciclovir tablets, no correlation was observed between ganciclovir AUC and reciprocal weight; oral dosing of valganciclovir tablets according to weight is not required. </p>
<p><span class="Italics">Metabolism: </span>Valganciclovir is rapidly hydrolyzed to ganciclovir; no other metabolites have been detected. No metabolite of orally administered radiolabeled ganciclovir (1000 mg single dose) accounted for more than 1% to 2% of the radioactivity recovered in the feces or urine. </p>
<p><span class="Italics">Elimination:</span> The major route of elimination of valganciclovir is by renal excretion as ganciclovir through glomerular filtration and active tubular secretion. Systemic clearance of intravenously administered ganciclovir was 3.07 ± 0.64 mL/min/kg (n=68) while renal clearance was 2.99 ± 0.67 mL/min/kg (n=16). </p>
<p>The terminal half-life (t<span class="Sub">½</span>) of ganciclovir following oral administration of valganciclovir tablets to either healthy or HIV-positive/CMV-positive subjects was 4.08 ± 0.76 hours (n=73), and that following administration of intravenous ganciclovir was 3.81 ± 0.71 hours (n=69). In heart, kidney, kidney-pancreas, and liver transplant patients, the terminal elimination half-life of ganciclovir following oral administration of valganciclovir was 6.48 ± 1.38 hours, and following oral administration of ganciclovir capsules was 8.56 ± 3.62 hours. </p>
<p>Specific Populations: </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> The pharmacokinetics of ganciclovir from a single oral dose of 900 mg valganciclovir tablets were evaluated in 24 otherwise healthy individuals with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
<p><span class="Bold">Table 11 Pharmacokinetics of Ganciclovir From a Single Oral Dose of 900 mg Valganciclovir Tablets</span></p>
<table cellpadding="0.8pt" width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Estimated Creatinine Clearance (mL/min)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Apparent Clearance (mL/min) Mean </span>± <span class="Bold">SD</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">AUC<span class="Sub">last</span> (mcg·h/mL) Mean </span>± <span class="Bold">SD</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Half-life (hours) Mean </span>± <span class="Bold">SD</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">51 to 70<br>21 to 50<br>11 to 20<br>≤10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6<br>6<br>6<br>6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">249 ± 99<br>136 ± 64<br>45 ± 11<br>12.8 ± 8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">49.5 ± 22.4<br>91.9 ± 43.9<br>223 ± 46<br>366 ± 66</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">4.85 ± 1.4<br>10.2 ± 4.4<br>21.8 ± 5.2<br>67.5 ± 34</p></td>
</tr>
</tbody>
</table>
<p>Decreased renal function results in decreased clearance of ganciclovir from valganciclovir, and a corresponding increase in terminal half-life. Therefore, dosage adjustment is required for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. </p>
<p>Hemodialysis reduces plasma concentrations of ganciclovir by about 50% following valganciclovir administration. Adult patients receiving hemodialysis (CrCl &lt;10 mL/min) cannot use valganciclovir tablets because the daily dose of valganciclovir tablets required for these patients is less than 450 mg [see <span class="Bold">Dosage and Administration <a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">(2.5)</a> and Use in Specific Populations <a href="#_f3d1b9d3-b7be-40a3-5fb1-826576d0e996">(8.6)</a></span>]. </p>
<p><span class="Italics">Pharmacokinetics in Pediatric Patients</span>: The pharmacokinetics of ganciclovir were evaluated following the administration of valganciclovir in 63 pediatric solid organ transplant patients aged 4 months to 16 years. In this study, patients received oral doses of valganciclovir (either valganciclovir for oral solution or tablets) to produce exposure equivalent to an adult 900 mg dose [see <span class="Bold">Dosage and Administration <a href="#_423e083e-18b4-6f88-1e63-91d42ec55a0a">(2.3)</a>, Adverse Reactions <a href="#_28a725fb-a1ac-9c41-06f1-2b3b548ee593">(6.2)</a>, Use in Specific Populations <a href="#_6fde80df-45f9-9142-74e7-613f8ddc8961">(8.4)</a>, Clinical Studies <a href="#_dd13e914-34d3-cf64-6db0-cfc621d25a2c">(14.2)</a></span>].</p>
<p>The pharmacokinetics of ganciclovir were similar across organ types and age ranges. Population pharmacokinetic modeling suggested that bioavailability was approximately 60%. Clearance was positively influenced by both body surface area and renal function. The mean total clearance was 5.3 L/hr (88.3 mL/min) for a patient with creatinine clearance of 70.4 mL/min. The mean Cmax and AUC by age and organ type are listed in <span class="Bold">Table 12</span>.</p>
<p><span class="Bold">Table 12 Mean (SD) Pharmacokinetics of Ganciclovir by Age in Pediatric Solid Organ Transplant Patients</span></p>
<table width="100%">
<col width="24%">
<col width="21%">
<col width="20%">
<col width="19%">
<col width="17%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="middle">
<p class="First"><span class="Bold"> </span></p>
<p><span class="Bold"> </span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">PK Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Age Group in Years</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">≤ 2 (n=2)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">&gt; 2 to &lt; 12 (n=10)<span class="Sup">a,b</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥ <span class="Bold">12 (n=19)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Kidney(N=31)</span><br></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">AUC<span class="Sub">0-24h </span>(μg<span class="Bold">·</span>h/mL)C<span class="Sub">max</span> (μg/mL)<br>t<span class="Sub">1/2</span>(h)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">67.6 (13.0)</p>
<p>10.4 (0.4) <br>4.5 (1.5)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">55.9 (12.1) </p>
<p>8.7 (2.1) <br>4.8 (1.0)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">47.8 (12.4)</p>
<p>7.7 (2.1)<br>6.0 (1.3)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"> </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≤ 2 (n=9)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">&gt; 2 to &lt; 12 (n=6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥ 12 (n=2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold">Liver(N=17)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">AUC<span class="Sub">0-24h </span>(μg<span class="Bold">·</span>h/mL)C<span class="Sub">max</span> (μg/mL)<br>t<span class="Sub">1/2</span> (h)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">69.9 (37.0)</p>
<p>11.9 (3.7)<br>2.8 (1.5)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">59.4 (8.1) <br>9.5 (2.3) <br>3.8 (0.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">35.4 (2.8)<br>5.5 (1.1)<br>4.4 (0.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First"><span class="Bold"> </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"> </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">≤ 2 (n=6)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">&gt; 2 to &lt; 12 (n=2)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">≥ <span class="Bold">12 (n=4)</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle"><p class="First"><span class="Bold">Heart(N=12)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">AUC<span class="Sub">0-24h </span>(μg<span class="Bold">·</span>h/mL)C<span class="Sub">max</span> (μg/mL)<br>t<span class="Sub">1/2</span> (h)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">55.4 (22.8) </p>
<p>8.2 (2.5) <br>3.8 (1.7)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">59.6 (21.0) </p>
<p>12.5 (1.2) <br>2.8 (0.9)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">60.6 (25.0) <br>9.5 (3.3) <br>4.9 (0.8)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>There was one subject in this age group who received both a kidney and liver transplant. The pharmacokinetic profile for this subject has not been included in this table as it is not possible to determine whether the effects observed are from the kidney/liver transplant or neither. </p>
<p><span class="Sup">b</span>The pharmacokinetic profiles for two subjects in this age group who received kidney transplants have not been included in this table as the data were determined to be non-evaluable.</p>
<p><span class="Italics">Pharmacokinetics in Geriatric Patients:</span> The pharmacokinetic characteristics of valganciclovir in elderly patients have not been established. Because elderly individuals frequently have a reduced glomerular filtration rate, renal function should be assessed before and during administration of valganciclovir [see <span class="Bold">Dosage and Administration <a href="#_593abd56-3dce-ee15-d7d1-5abd414b82af">(2.5)</a>, Use in Specific Populations <a href="#GERIATRIC_USE">(8.5)</a></span>]. </p>
<p>Drug Interactions: </p>
<p><span class="Italics">In vivo</span> drug-drug interaction studies were not conducted with valganciclovir. However, because valganciclovir is rapidly and extensively converted to ganciclovir, interactions associated with ganciclovir will be expected for valganciclovir  [see <span class="Bold">Drug Interactions <a href="#DRUG_INTERACTIONS">(7)</a></span>]. </p>
<p>Drug-drug interaction studies were conducted in patients with normal renal function. Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> may have increased concentrations of ganciclovir and the coadministered drug following concomitant administration of valganciclovir and drugs excreted by the same pathway as ganciclovir. Therefore, these patients should be closely monitored for toxicity of ganciclovir and the coadministered drug. </p>
<p><span class="Bold">Table 13 </span>and <span class="Bold">Table 14 </span>provide a listing of established drug interaction studies with ganciclovir. <span class="Bold">Table 13 </span>provides the effects of coadministered drug on ganciclovir plasma pharmacokinetic parameters, whereas <span class="Bold">Table 14 </span>provides the effects of ganciclovir on plasma pharmacokinetic parameters of co-administered drug. </p>
<p><span class="Bold">Table 13 Results of Drug Interaction Studies With Ganciclovir: Effects of Coadministered Drug on Ganciclovir Pharmacokinetic Parameters</span></p>
<table cellpadding="0.4pt" cellspacing="0pt" width="100%">
<col width="25%">
<col width="18%">
<col width="19%">
<col width="38%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Coadministered Drug</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Ganciclovir Dosage</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Ganciclovir Pharmacokinetic (PK) Parameter</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle">
<p class="First">Zidovudine 100 mg </p>
<p>every 4 hours </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1000 mg every 8 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">AUC ↓ 17 ± 25% <br>(range: -52% to 23%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle"><p class="First">Probenecid 500 mg every 6 hours </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1000 mg every 8 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">AUC ↑ 53 ± 91% <br>(range: -14% to 299%) <br>Ganciclovir renal clearance ↓ 22 ± 20% <br>(range: -54% to -4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle">
<p class="First">Mycophenolate </p>
<p>Mofetil (MMF) </p>
<p>1.5 g single dose </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">IV ganciclovir 5 mg/kg single dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">No effect on ganciclovir PK parameters observed(patients with normal renal function)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="middle">
<p class="First">Didanosine 200 mg </p>
<p>every 12 hours </p>
<p>administered </p>
<p>2 hours before ganciclovir </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1000 mg every 8 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">AUC ↓ 21 ± 17% <br>(range: -44% to 5%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="3" valign="top">
<p class="First">Didanosine 200 mg every 12 hours simultaneously administered with </p>
<p>ganciclovir </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1000 mg every 8 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">No effect on ganciclovir PK parameters observed</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">IV ganciclovir 5 mg/kg twice daily</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">No effect on ganciclovir PK parameters observed</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">IV ganciclovir 5 mg/kg once daily</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">No effect on ganciclovir PK parameters observed</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="middle">
<p class="First">Trimethoprim </p>
<p>200 mg once daily </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">1000 mg every 8 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First">Ganciclovir renal clearance ↓ 16.3% <br>Half-life ↑15%</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Table 14 Results of Drug Interaction Studies With Ganciclovir: Effects of Ganciclovir on Pharmacokinetic Parameters of Coadministered Drug</span></p>
<table cellpadding="0.5pt" width="100%">
<col width="28%">
<col width="20%">
<col width="19%">
<col width="34%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Coadministered Drug</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Ganciclovir Dosage</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Coadministered Drug Pharmacokinetic (PK) Parameter</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Zidovudine 100 mg </p>
<p>every 4 hours</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1000 mg every <br>8 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">AUC<span class="Sub">0-4</span> ↑ 19 ± 27% <br>(range: -11% to 74%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Mycophenolate </p>
<p>Mofetil (MMF) </p>
<p>1.5 g single dose</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">IV ganciclovir 5 mg/kg single dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">No PK interaction observed (patients with normal renal function)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Didanosine 200 mg every 12 hours when administered 2 hours prior to or concurrent with ganciclovir</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1000 mg every <br>8 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">AUC<span class="Sub">0-12</span> ↑111 ± 114% <br>(range: 10% to 493%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Didanosine 200 mg every 12 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">IV ganciclovir 5 mg/kg twice daily</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">AUC<span class="Sub">0-12</span> ↑70 ± 40% <br>(range: 3% to 121%) <br>C<span class="Sub">max</span>↑49 ± 48% <br>(range: -28% to 125%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Didanosine 200 mg every 12 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">IV ganciclovir 5 mg/kg once daily</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">AUC<span class="Sub">0-12</span> ↑50 ± 26% <br>(range: 22% to 110%)  <br>C<span class="Sub">max</span> ↑36 ± 36% <br>(range: -27% to 94%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Trimethoprim </p>
<p>200 mg once daily </p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1000 mg every <br>8 hours </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Increase (12%) in C<span class="Sub">min</span></p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_845af12b-4be2-e876-d9ca-5d9b616564c4"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First">Mechanism of Action: Valganciclovir is an L-valyl ester (prodrug) of ganciclovir that exists as a mixture of two diastereomers. After oral administration, both diastereomers are rapidly converted to ganciclovir by intestinal and hepatic esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, which inhibits replication of human CMV in cell culture and <span class="Italics">in vivo</span>. </p>
<p>In CMV-infected cells ganciclovir is initially phosphorylated to ganciclovir monophosphate by the viral protein kinase, pUL97. Further phosphorylation occurs by cellular kinases to produce ganciclovir triphosphate, which is then slowly metabolized intracellularly (half-life 18 hours). As the phosphorylation is largely dependent on the viral kinase, phosphorylation of ganciclovir occurs preferentially in virus-infected cells. The virustatic activity of ganciclovir is due to inhibition of the viral DNA polymerase, pUL54, synthesis by ganciclovir triphosphate. </p>
<p>Antiviral Activity: The quantitative relationship between the cell culture susceptibility of human herpes viruses to antivirals and clinical response to antiviral therapy has not been established, and virus sensitivity testing has not been standardized. Sensitivity test results, expressed as the concentration of drug required to inhibit the growth of virus in cell culture by 50% (EC50), vary greatly depending upon a number of factors including the assay used. Thus, the reported EC50 values of ganciclovir that inhibit human CMV replication in cell culture (laboratory and clinical isolates) have ranged from 0.08 to 22.94 μM (0.02 to 5.75 mcg/mL). The distribution and range in susceptibility observed in one assay evaluating 130 clinical isolates was 0 to 1 μM (35%), 1.1 to 2 μM (20%), 2.1 to 3 μM (27%), 3.1 to 4 μM (13%), 4.1 to 5 μM (5%), &gt; 5 μM (&lt;1%). Ganciclovir inhibits mammalian cell proliferation (CIC50) in cell culture at higher concentrations ranging from 40 to &gt; 1,000 μM (10.21 to &gt; 250 mcg/mL). Bone marrow-derived colony-forming cells are more sensitive [CIC<span class="Sub">50</span> value = 2.7 to 12 μM (0.69 to 3.06 mcg/mL)]. </p>
<p>Viral Resistance:</p>
<p>Cell culture: CMV isolates with reduced susceptibility to ganciclovir have been selected in cell culture. Growth of CMV <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> in the presence of ganciclovir resulted in the selection of amino acid substitutions in the viral protein kinase pUL97 (M460I/V, L595S, G598D, and K599T) and the viral DNA polymerase pUL54 (D301N, N410K, F412V, P488R, L516R, C539R, L545S, F595I, V812L, P829S, L862F, D879G, and V946L).</p>
<p><span class="Italics">In vivo</span>: Viruses resistant to ganciclovir can arise after prolonged treatment or prophylaxis with valganciclovir by selection of substitutions in pUL97 and/or pUL54. Limited clinical data are available on the development of clinical resistance to ganciclovir and many pathways to resistance likely exist. In clinical isolates, seven canonical pUL97 substitutions, (M460V/I, H520Q, C592G, A594V, L595S, C603W) are the most frequently reported ganciclovir resistance-associated substitutions. These and other substitutions less frequently reported in the literature, or observed in clinical trials, are listed in <span class="Bold">Table 15</span></p>
<p><span class="Bold">Table 15: Summary of Resistance-associated Amino Acid Substitutions Observed in the CMV of Patients Failing Ganciclovir Treatment or Prophylaxis</span></p>
<table width="100%">
<col width="13%">
<col width="87%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">pUL97 </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">L405P, A440V, M460I/V, V466G/M, H520Q, del 590-593, A591D/V, C592G, A594E/G/T/V/P, L595F/S/T/W, del 595, del 595-603, E596D/G, K599E/M, del 600- 601, del 597-600, del 601-603, C603W/R/S/Y, C607F/S/Y</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">pUL54 </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">E315D, N408D/K/S, F412C/L/S, D413A/E, L501F/I, T503I, K513E/N/R, I521T, P522A/L/S, L545S/W, Q578H/L, D588E/N, G629S, S695T, I726T/V, E756K, V781I, V787L, L802M, A809V, T813S, T821I, A834P, G841A/S, D879G, A972V, del 981-982, A987G</p></td>
</tr>
</tbody>
</table>
<p>Note: Many additional pathways to ganciclovir resistance likely exist  </p>
<p>The presence of known ganciclovir resistance-associated amino acid substitutions was evaluated in a study that extended valganciclovir CMV prophylaxis from 100 days to 200 days post-transplant in adult kidney transplant patients at high risk for CMV disease (D+/R-) [see <span class="Bold">Clinical Studies <a href="#_87580389-2261-aef1-9a8b-92c42c8a3a7b">(14.1)</a></span>]. Five subjects from the 100 day group and four subjects from the 200 day group meeting the resistance analysis criteria had known ganciclovir resistance-associated amino acid substitutions detected. In six subjects, the following resistance-associated amino acid substitutions were detected within pUL97: 100 day group: A440V, M460V, C592G; 200 day group: M460V, C603W. In three subjects, the following resistance-associated amino acid substitutions were detected within pUL54: 100 day group: E315D, 200 day group: E315D, P522S. Overall, the detection of known ganciclovir resistance-associated amino acid substitutions was observed more frequently in patients during prophylaxis therapy than after the completion of prophylaxis therapy (during therapy: 5/12 [42%] versus after therapy: 4/58 [7%]). The possibility of viral resistance should be considered in patients who show poor clinical response or experience persistent viral excretion during therapy. </p>
<p>Cross-Resistance: Cross-resistance has been reported for amino acid substitutions selected in cell culture by ganciclovir, cidofovir or foscarnet. In general, amino acid substitutions in pUL54 conferring cross-resistance to ganciclovir and cidofovir are located within the exonuclease domains and region V. Whereas, amino acid substitutions conferring cross-resistance to foscarnet are diverse, but concentrate at and between regions II (codon 696-742) and III (codon 805-845). The amino acid substitutions that resulted in reduced susceptibility to ganciclovir and either cidofovir and/or foscarnet are summarized in <span class="Bold">Table 16</span>.</p>
<p><span class="Bold">Table 16 Summary of pUL54 Amino Acid Substitutions with Cross-Resistance between Ganciclovir, Cidofovir, and/or Foscarnet</span></p>
<table width="100%">
<col width="28%">
<col width="72%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cross-resistant to cidofovir </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">D301N, N408D/K, N410K, F412C/L/S/V, D413E, L501I, T503I, K513E/N, L516R, I521T, P522S/A, L545S/W, Q578H, D588N, I726T/V, E756K, V812L, T813S, A834P, G841A, del 981-982, A987G</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cross-resistant to foscarnet </span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">F412C, Q578H/L, D588N, E756K, V781I, V787L, L802M, A809V, V812L, T813S, T821I, A834P, G841A, del 981-982</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="NONCLINICAL_TOXICOLOGY"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="CARCINOGENESIS_AND_MUTAGENESIS_AND_IMPAIRMENT_OF_FERTILITY"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility</h2>
<p class="First">Long-term carcinogenicity studies have not been conducted with valganciclovir . However, upon oral administration, valganciclovir is rapidly and extensively converted to ganciclovir. Therefore, like ganciclovir, valganciclovir is a potential carcinogen. </p>
<p>Ganciclovir was carcinogenic in the mouse at oral doses that produced exposures approximately 0.1x and 1.4x, respectively, the mean drug exposure in humans following the recommended intravenous dose of 5 mg/kg, based on area under the plasma concentration curve (AUC) comparisons. At the higher dose there was a significant increase in the incidence of tumors of the preputial gland in males, forestomach (nonglandular mucosa) in males and females, and reproductive tissues (ovaries, uterus, mammary gland, clitoral gland and vagina) and liver in females. At the lower dose, a slightly increased incidence of tumors was noted in the preputial and harderian glands in males, forestomach in males and females, and liver in females. Ganciclovir should be considered a potential carcinogen in humans. </p>
<p>Valganciclovir increases mutations in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells. In the mouse micronucleus assay, valganciclovir was clastogenic. Valganciclovir was not mutagenic in the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> assay. Ganciclovir increased mutations in mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells and DNA damage in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> <span class="Italics">in vitro</span>. In the mouse micronucleus assay, ganciclovir was clastogenic. Ganciclovir was not mutagenic in the Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> assay. </p>
<p>Valganciclovir is converted to ganciclovir and therefore is expected to have similar reproductive toxicity effects as ganciclovir [see <span class="Bold">Warnings and Precautions <a href="#_06a3bb9b-72b3-372c-7d37-5d7e4c0fb67f">(5.2)</a></span>]. Ganciclovir caused decreased mating behavior, decreased fertility, and an increased incidence of embryolethality in female mice following intravenous doses that produced an exposure approximately 1.7x the mean drug exposure in humans following the dose of 5 mg/kg, based on AUC comparisons. Ganciclovir caused decreased fertility in male mice and hypospermatogenesis in mice and dogs following daily oral or intravenous administration. Systemic drug exposure (AUC) at the lowest dose showing toxicity in each species ranged from 0.03 to 0.1x the AUC of the recommended human intravenous dose. Valganciclovir caused similar effects on spermatogenesis in mice, rats, and dogs. It is considered likely that ganciclovir (and valganciclovir) could cause inhibition of human spermatogenesis. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_d2d681ae-b4ae-5778-9c6f-af22611a78d7"></a><a name="section-12.2"></a><p></p>
<h2>13.3 Reproductive and Developmental Toxicology </h2>
<p class="First">Valganciclovir is converted to ganciclovir and therefore is expected to have reproductive toxicity effects similar to ganciclovir. Ganciclovir has been shown to be embryotoxic in rabbits and mice following intravenous administration, and teratogenic in rabbits. Fetal resorptions were present in at least 85% of rabbits and mice administered doses that produced 2x the human exposure based on AUC comparisons (all dose comparisons presented are based on the human AUC following administration of a single 5 mg/kg infusion of intravenous ganciclovir). Effects observed in rabbits included: <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span>, embryolethality, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> and/or maternal toxicity. Teratogenic changes included <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>/<span class="product-label-link" type="condition" conceptid="376512" conceptname="Microphthalmos">microphthalmia</span>, aplastic organs (kidney and pancreas), <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span> and brachygnathia. In mice, effects observed were maternal/fetal toxicity and embryolethality. </p>
<p>Daily intravenous doses administered to female mice prior to mating, during gestation, and during lactation caused hypoplasia of the testes and seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> in the month-old male offspring, as well as pathologic changes in the nonglandular region of the stomach [see <span class="Bold">Warnings and Precautions <a href="#_bf09797e-c0bf-46f1-6c27-2130536e9d66">(5.3)</a></span>]. The drug exposure in mice as estimated by the AUC was approximately 1.7x the human AUC. </p>
<p>Data obtained using an ex vivo human placental model show that ganciclovir crosses the placenta and that simple diffusion is the most likely mechanism of transfer. The transfer was not saturable over a concentration range of 1 to 10 mg/mL and occurred by passive diffusion. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CLINICAL_STUDIES"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_87580389-2261-aef1-9a8b-92c42c8a3a7b"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adult Patients </h2>
<p class="First">Induction Therapy of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span>: In one randomized open-label controlled study, 160 patients with AIDS and newly diagnosed <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> were randomized to receive treatment with either valganciclovir tablets (900 mg twice daily for 21 days, then 900 mg once daily for 7 days) or with intravenous ganciclovir solution (5 mg/kg twice daily for 21 days, then 5 mg/kg once daily for 7 days). Study participants were: male (91%), White (53%), Hispanic (31%), and Black (11%). The median age was 39 years, the median baseline HIV-1 RNA was 4.9 log10, and the median CD4 cell count was 23 cells/mm<span class="Sup">3</span>. A determination of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> progression by the masked review of retinal photographs taken at baseline and Week 4 was the primary outcome measurement of the 3-week induction therapy. <span class="Bold">Table 17 </span>provides the outcomes at 4 weeks.</p>
<p><span class="Bold">Table 17 Week 4 Masked Review of Retinal Photographs in <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span> Study</span></p>
<table cellpadding="0.5pt" cellspacing="0pt" width="100%">
<col width="43%">
<col width="27%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Intravenous Ganciclovir</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Valganciclovir Tablets</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Determination of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> </p>
<p>progression at Week 4 </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N=80</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N=80</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Progressor <br>Non-progressor </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">7</p>
<p>63</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">7</p>
<p>64</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> </p>
<p>Discontinuations due to Adverse Events </p>
<p>Failed to return </p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">2</p>
<p>1</p>
<p>1</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">1</p>
<p>2</p>
<p>1</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">CMV not confirmed at baseline or no interpretable baseline photos </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5</p></td>
</tr>
</tbody>
</table>
<p>Maintenance Therapy of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span>: No comparative clinical data are available on the efficacy of valganciclovir tablets for the maintenance therapy of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> because all patients in the <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> study received open-label valganciclovir tablets after Week 4. However, the AUC for ganciclovir is similar following administration of 900 mg valganciclovir tablets once daily and 5 mg/kg intravenous ganciclovir once daily. Although the ganciclovir C<span class="Sub">max</span> is lower following valganciclovir tablets administration compared to intravenous ganciclovir, it is higher than the Cmax obtained following oral ganciclovir administration [see <span class="Bold">Figure 1 in Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. Therefore, use of valganciclovir tablets as maintenance therapy is supported by a plasma concentration-time profile similar to that of two approved products for maintenance therapy of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. </p>
<p>Prevention of CMV Disease in Heart, Kidney, Kidney-Pancreas, or Liver Transplantation: A double blind, double-dummy active comparator study was conducted in 372 heart, liver, kidney, or kidney-pancreas transplant patients at high risk for CMV disease (D+/R-). Patients were randomized (2 valganciclovir : 1 oral ganciclovir) to receive either valganciclovir tablets (900 mg once daily) or oral ganciclovir (1000 mg three times a day) starting within 10 days of transplantation until Day 100 post-transplant. The proportion of patients who developed CMV disease, including CMV syndrome and/or tissue-invasive disease during the first 6 months post-transplant was similar between the valganciclovir tablets arm (12.1%, N=239) and the oral ganciclovir arm (15.2%, N=125). However, in liver transplant patients, the incidence of tissue-invasive CMV disease was significantly higher in the valganciclovir group compared with the ganciclovir group. These results are summarized in <span class="Bold">Table 18</span>. </p>
<p>Mortality at six months was 3.7% (9/244) in the valganciclovir group and 1.6% (2/126) in the oral ganciclovir group.</p>
<p><span class="Bold">Table 18 Percentage of Patients With CMV Disease, Tissue-Invasive CMV Disease or CMV syndrome by Organ Type: Endpoint Committee, 6 Month ITT Population</span></p>
<table width="100%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">CMV Disease<span class="Sup">1</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Tissue-Invasive CMV Disease</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">CMV Syndrome<span class="Sup">2</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Organ</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">VGCV</span></p>
<p><span class="Bold">(N=239)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">GCV</span></p>
<p><span class="Bold">(N=125)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">VGCV</span></p>
<p><span class="Bold">(N=239)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">GCV</span></p>
<p><span class="Bold">(N=125)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">VGCV</span></p>
<p><span class="Bold">(N=239)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">GCV</span></p>
<p><span class="Bold">(N=125)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Liver</p>
<p>(n=177)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">19%</p>
<p>(22 / 118)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">12%</p>
<p>(7 / 59)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">14%</p>
<p>(16 / 118)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">3%</p>
<p>(2 / 59)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">5%</p>
<p>(6 / 118)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">9%</p>
<p>(5 / 59)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Kidney</p>
<p>(n=120)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">6%</p>
<p>(5 / 81)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">23%</p>
<p>(9 / 39)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">1%</p>
<p>(1 / 81)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">5%</p>
<p>(2 / 39)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">5%</p>
<p>(4 / 81)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">18%</p>
<p>(7 / 39)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Heart</p>
<p>(n=56)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">6%</p>
<p>(2 / 35)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">10%</p>
<p>(2 / 21)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">0%</p>
<p>(0 / 35)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">5%</p>
<p>(1 / 21)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">6%</p>
<p>(2 / 35)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">5%</p>
<p>(1 / 21)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Kidney / Pancreas</p>
<p>(n=11)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">0%</p>
<p>(0 / 5)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">17%</p>
<p>(1 / 6)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">0%</p>
<p>(0 / 5)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">17%</p>
<p>(1 / 6)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">0%</p>
<p>(0 / 5)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">0%</p>
<p>(0 / 6)</p>
</td>
</tr>
</tbody>
</table>
<p>GCV = oral ganciclovir; VGCV = valganciclovir </p>
<p><span class="Sup">1</span>Number of patients with CMV disease = Number of patients with tissue-invasive CMV disease or CMV syndrome </p>
<p><span class="Sup">2</span>CMV syndrome was defined as evidence of <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> accompanied with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> ≥ 38°C on two or more occasions separated by at least 24 hours within a 7-day period and one or more of the following: <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, atypical <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and elevation of hepatic transaminases</p>
<p>Prevention of CMV Disease in Kidney Transplantation: A double-blind, placebo-controlled study was conducted in 326 kidney transplant patients at high risk for CMV disease (D+/R-) to assess the efficacy and safety of extending valganciclovir CMV prophylaxis from 100 to 200 days post-transplant. Patients were randomized (1:1) to receive valganciclovir tablets (900 mg once daily) within 10 days of transplantation either until Day 200 post-transplant or until Day 100 post-transplant followed by 100 days of placebo. Extending CMV prophylaxis with valganciclovir until Day 200 post-transplant demonstrated superiority in preventing CMV disease within the first 12 months post-transplant in high risk kidney transplant patients compared to the 100 day dosing regimen (primary endpoint). These results are summarized in <span class="Bold">Table 19. </span></p>
<p><span class="Bold">Table 19 Percentage of Kidney Transplant Patients With CMV Disease, Tissue-Invasive CMV Disease or CMV Syndrome, 12 Month ITT Population</span></p>
<table width="100%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">CMV Disease<span class="Sup">1</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Tissue-Invasive CMV </span></p>
<p><span class="Bold">Disease</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">CMV Syndrome<span class="Sup">2</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">100 Days <br>VGCV <br>(N=163)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">200 Days </p>
<p>VGCV <br>(N=155)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">100 Days <br>VGCV <br>(N=163)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">200 Days VGCV (N=155)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">100 Days VGCV (N=163)</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">200Days</p>
<p>VGCV (N=155)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Cases </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">36.8% <br>(60/163) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">16.8% <br>(26/155) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.8% <br>(3/163)3 </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">0.6% </p>
<p>(1/155) </p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">35. 0% (57/163) </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">16.1% (25/155) </p></td>
</tr>
</tbody>
</table>
<p>VGCV = valganciclovir. </p>
<p><span class="Sup">1</span>Number of patients with CMV disease = Number of patients with tissue-invasive CMV disease or CMV syndrome </p>
<p><span class="Sup">2</span>CMV syndrome was defined as evidence of <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> accompanied with at least one of the following: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (≥ 38°C), severe <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, atypical <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and elevation of hepatic transaminases </p>
<p><span class="Sup">3</span>Two patients in the 100 day group had both tissue-invasive CMV disease and CMV syndrome; however, these patients are counted as having only tissue-invasive CMV disease. </p>
<p>The percentage of kidney transplant patients with CMV disease at 24 months post-transplant was 38.7% (63/163) for the 100 day dosing regimen and 21.3% (33/155) for the 200 day dosing regimen. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_dd13e914-34d3-cf64-6db0-cfc621d25a2c"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Pediatric Patients</h2>
<p class="First">Prevention of CMV in Pediatric Solid Organ Transplant Recipients:<span class="Underline"></span>Sixty-three children, 4 months to 16 years of age, who had a solid organ transplant (kidney 33, liver 17, heart 12, and kidney/liver 1) and were at risk for developing CMV disease, were enrolled in an open-label, safety, and pharmacokinetic study of oral valganciclovir (valganciclovir for oral solution or tablets). Patients received valganciclovir once daily as soon as possible after transplant until a maximum of 100 days post-transplant. The daily doses of valganciclovir were calculated at each study visit based on body surface area and a modified creatinine clearance [see <span class="Bold">Dosage and Administration <a href="#_423e083e-18b4-6f88-1e63-91d42ec55a0a">(2.3)</a></span>].</p>
<p>The pharmacokinetics of ganciclovir were similar across organ transplant types and age ranges. The mean daily ganciclovir exposures in pediatric patients were comparable to those observed in adult solid organ transplant patients receiving valganciclovir 900 mg once daily [see <span class="Bold">Clinical Pharmacology <a href="#PHARMACOKINETICS">(12.3)</a></span>]. No case of CMV disease was reported during the study. <span class="product-label-link" type="condition" conceptid="45757222" conceptname="Cytomegalovirus viraemia">CMV viremia</span> was reported in 7 (11%) patients during the study; however, none of these events fulfilled the definition of CMV syndrome. Based on the pharmacokinetic, safety, and efficacy data from this study and extrapolated efficacy data from the adult study, oral valganciclovir is indicated for the prevention of CMV disease in kidney and heart transplant children 4 months to 16 years of age at risk for developing CMV disease. valganciclovir is not approved in adults for CMV prophylaxis in liver transplant patients; therefore, valganciclovir is not recommended for CMV prophylaxis in pediatric liver transplant patients because efficacy cannot be extrapolated from adults.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="REFERENCES"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>•</dt>
<dd>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165. </dd>
<dt>•</dt>
<dd>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html </dd>
<dt>•</dt>
<dd>American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006; 63:1172-1193. </dd>
<dt>•</dt>
<dd>Polovich, M., White, J. M., &amp; Kelleher, L.O. (eds.). 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd ed.). Pittsburgh, PA: Oncology Nursing Society. </dd>
<dt>•</dt>
<dd>Drew A.L., Miner R., Saleh E. 1993. Antiviral Susceptibility Testing of Cytomegalovirus Criteria for Detecting Resistance to Antivirals. Clinical Diagnostic Virology 1:179-185. </dd>
<dt>•</dt>
<dd>Hakki M., Chou, S. The biology of cytomegalovirus <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>. Curr Opinion in Infectious Dis. 2011; 24:605-611.</dd>
<dt>•</dt>
<dd>Lurain, N.S., Chou, S. Antiviral <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> of humancytomegalovirus. Clin Microbiol Rev. 2010; 23(4):689-712.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="HOW_SUPPLIED"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Valganciclovir Tablets USP, 450 mg are pink colored, oval shaped, film coated tablets debossed with ‘RDY’ on one side and ‘762’ on other side, and are supplied in unit dose packages of 30 (5 x 6) NDC 68084-965-25</p>
<p>Store at 20°C-25°C (68°F-77°F) [See USP Controlled Room Temperature]. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="INFORMATION_FOR_PATIENTS"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <span class="Bold"><a href="#_005f356e-6a86-9980-00c5-335fa7f8e15c">FDA-Approved Patient Labeling</a></span></p>
<p><span class="Bold">Valganciclovir tablets cannot be substituted for ganciclovir capsules on a one-to-one basis. </span>Inform patients switching from ganciclovir capsules of the risk of overdosage if they take more than the prescribed number of valganciclovir tablets [see <span class="Bold">Dosage and Administration <a href="#_61051f57-8ca3-f04c-82c8-4ab291b78984">(2.1)</a>, Overdosage <a href="#OVERDOSAGE">(10)</a></span>]. </p>
<p>Adult patients should use valganciclovir tablets, not valganciclovir for oral solution [see <span class="Bold">Dosage and Administration <a href="#_61051f57-8ca3-f04c-82c8-4ab291b78984">(2.1)</a></span>].</p>
<p>Valganciclovir is changed to ganciclovir once it is absorbed into the body. Inform all patients that the major toxicities of ganciclovir include <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and that dose modifications may be required, including discontinuation. The importance of close monitoring of blood counts while on therapy should be emphasized. Inform patients that ganciclovir has been associated with elevations in serum creatinine. </p>
<p>Instruct patients to take valganciclovir with food to maximize bioavailability. </p>
<p>Advise patients that ganciclovir causes decreased sperm production in animals and may cause decreased fertility in humans. Advise women of childbearing potential that ganciclovir causes <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in animals and should not be used during pregnancy. Because of the potential for serious adverse events in nursing infants, instruct mothers not to breast-feed if they are receiving valganciclovir. Advise women of childbearing potential to use effective contraception during and for at least 30 days following treatment with valganciclovir . Similarly, advise men to practice barrier contraception during and for at least 90 days following treatment with valganciclovir. </p>
<p>Although there is no information from human studies, advise patients that ganciclovir should be considered a potential carcinogen. </p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, sedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> and/or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> have been reported with the use of valganciclovir and/or ganciclovir. If they occur, tasks requiring alertness may be affected including the patient’s ability to drive and operate machinery. </p>
<p>Inform patients that ganciclovir is not a cure for <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, and they may continue to experience progression of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> during or following treatment. Advise patients to have ophthalmologic follow-up examinations at a minimum of every 4 to 6 weeks while being treated with valganciclovir. Some patients will require more frequent follow-up. </p>
<p>Rx Only</p>
<p><span class="Bold">PACKAGING INFORMATION</span></p>
<p>American Health Packaging unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> (see <a href="#HOW_SUPPLIED">How Supplied</a> section) contains drug product from Dr. Reddy’s<br>Laboratories Limited as follows:<br>(450 mg/ 30 UD) NDC 68084-965-25 packaged from NDC 55111-762</p>
<p>Packaged and Distributed by: <br><span class="Bold">American Health Packaging</span>                         <br>Columbus, OH 43217        </p>
<p>8296525/1214</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="_005f356e-6a86-9980-00c5-335fa7f8e15c"></a><a name="section-17"></a><p></p>
<h1>FDA-Approved Patient Labeling<br>Patient Information<br>Valganciclovir Tablets USP </h1>
<p class="First">Read the Patient Information that comes with valganciclovir before you start using it and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor. </p>
<p><span class="Bold">What is the most important information I should know about valganciclovir? </span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Valganciclovir can affect your blood cells and bone marrow causing serious and life-threatening problems. </span>Valganciclovir can lower the amount of your white blood cells, red blood cells, and platelets. Your doctor may do regular blood tests to check your blood cells while you are taking valganciclovir. Based on these tests, your doctor may change your dose or tell you to stop taking valganciclovir. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Valganciclovir may cause cancer.</span> Valganciclovir causes cancer in animals. It is not known if Valganciclovir causes cancer in people. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Valganciclovir may cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. </span>Valganciclovir causes <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in animals. It is not known if valganciclovir causes <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in people. <span class="Bold">If you are pregnant, talk to your doctor before taking valganciclovir. </span><dl>
<dt>•</dt>
<dd><span class="Bold">Tell your doctor right away if you become pregnant while taking valganciclovir. </span></dd>
<dt>•</dt>
<dd><span class="Bold">If you are a female who can become pregnant, you should use effective birth control during treatment with valganciclovir and for at least 30 days after treatment. </span></dd>
<dt>•</dt>
<dd>
<span class="Bold">Men should use a condom during treatment with valganciclovir , and for at least 90 days after treatment, if their female sexual partner can become pregnant. </span>Talk to your doctor if you have questions about birth control.</dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="Bold">Valganciclovir may lower the amount of sperm in a man’s body and cause fertility problems. </span></dd>
<dt>•</dt>
<dd>
<span class="Bold">Valganciclovir can affect your kidney, including serious problems such as <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>. </span>Your doctor may do regular blood tests to check your kidney function while you are taking valganciclovir. Your doctor may adjust your dose based on these tests. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Valganciclovir changes into the medicine ganciclovir once it is in your body. </span>Ganciclovir is also the active ingredient in Cytovene<span class="Sup">®</span>-IV and ganciclovir capsules. Do not take ganciclovir capsules or Cytovene-IV if you are taking valganciclovir . The dose of medicine in valganciclovir tablets and ganciclovir capsules is different. <span class="Bold">One tablet of valganciclovir has more medicine than one capsule of ganciclovir</span>. <span class="Bold">This means that one valganciclovir tablet cannot be substituted for one ganciclovir capsule. You could <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and become very sick if valganciclovir is taken with ganciclovir capsules or Cytovene-IV. </span>Talk to your doctor or pharmacist if you have questions about your medicine. </dd>
</dl>
<p><span class="Bold">What is valganciclovir? </span><br></p>
<p>Valganciclovir is an “antiviral? medicine. <br>In adults, valganciclovir tablets are used: </p>
<dl>
<dt>•</dt>
<dd>to treat cytomegalovirus (CMV) <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> in people who have <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS). When CMV virus infects the eyes, it is called <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. If <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> is left untreated, it can cause <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>. </dd>
<dt>•</dt>
<dd>to prevent cytomegalovirus (CMV) disease in people who have received a <span class="Bold">heart, kidney, or kidney-pancreas </span>transplant and who have a high risk for getting CMV disease. </dd>
</dl>
<p>In children (4 months to 16 years of age) valganciclovir tablets used:  </p>
<dl>
<dt>•</dt>
<dd>to prevent cytomegalovirus (CMV) disease in children who have received a <span class="Bold">heart or kidney </span>transplant and have a high risk for getting CMV disease. </dd>
</dl>
<p>Valganciclovir is not for use in adults or children who have received a liver transplant.<br>It is not known if valganciclovir is safe and effective: </p>
<dl>
<dt>•</dt>
<dd>to prevent CMV disease in people who have had other types of organ transplants such as lung or intestine. </dd>
<dt>•</dt>
<dd>to prevent CMV disease in children under 4 months of age who receive an organ transplant. </dd>
<dt>•</dt>
<dd>to treat CMV disease that a baby might be born with (congenital CMV disease) </dd>
<dt>•</dt>
<dd>in adults older than age 65. </dd>
</dl>
<p><span class="Bold">Valganciclovir does not cure <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. </span>You may still get <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> or worsening of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> during or after treatment with valganciclovir. It is important to stay under a doctor’s care and have your eyes checked regularly. </p>
<p><span class="Bold">Who should not take valganciclovir? </span></p>
<p><span class="Bold">Do not take valganciclovir tablets if you are receiving hemodialysis. </span>The use of ganciclovir capsules rather than valganciclovir tablets are recommended. </p>
<p><span class="Bold">Do not take valganciclovir if you are allergic to any of its ingredients or if you have ever had a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ganciclovir capsules or Cytovene-IV. </span>Symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to valganciclovir may include: sudden trouble breathing, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> all over your body, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> around your mouth, or feeling anxious. </p>
<p>See the end of this leaflet for a list of the ingredients in valganciclovir. </p>
<p><span class="Bold">What should I tell my doctor before taking valganciclovir? </span></p>
<p><span class="Bold">Before taking valganciclovir, tell your doctor if you: </span></p>
<dl>
<dt>•</dt>
<dd>have kidney problems. Your doctor may give you a lower dose of valganciclovir , or check you more often if you are taking valganciclovir . </dd>
<dt>•</dt>
<dd>have blood cell problems </dd>
<dt>•</dt>
<dd>are having radiation treatment </dd>
<dt>•</dt>
<dd>have any other medical conditions</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if valganciclovir<span class="Bold"></span>causes <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in an unborn baby. <span class="Bold">Tell your doctor right away if you become pregnant while taking valganciclovir. See “What is the most important information I should know about valganciclovir?? </span>
</dd>
<dt>•</dt>
<dd>are breast-feeding or plan to breast-feed. It is not known if valganciclovir passes into your milk and if it may harm your baby. You should not breast-feed if you are HIV-positive because of the chance of passing the HIV virus to your baby through your milk. </dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and non-prescription medicines, vitamins and herbal supplements. Valganciclovir and other medicines may affect each other and cause serious side effects. Especially tell your doctor if you take: </p>
<dl>
<dt>•</dt>
<dd>didanosine (Videx<span class="Sup">®</span>) </dd>
<dt>•</dt>
<dd>zidovudine (Retrovir<span class="Sup">®</span>, Trizivir, Combivir) </dd>
<dt>•</dt>
<dd>probenecid (Col-Probenecid, Probenacid and Colchicine) </dd>
<dt>•</dt>
<dd>mycophenolate mofetil (CellCept<span class="Sup">®</span>) </dd>
</dl>
<p><span class="Bold">How should I take valganciclovir? </span></p>
<dl>
<dt>•</dt>
<dd>Take valganciclovir exactly as your doctor prescribes it. Your dose of valganciclovir will depend on your medical condition. </dd>
<dt>•</dt>
<dd>Adults should only take valganciclovir tablets. Children may take either valganciclovir tablets or oral solution.</dd>
<dt>•</dt>
<dd>Take valganciclovir with food. </dd>
<dt>•</dt>
<dd>Do not break or crush valganciclovir tablets. Avoid contact with your skin or eyes. If you come in contact with the contents of the tablet, wash your skin well with soap and water or rinse your eyes well with plain water. </dd>
<dt>•</dt>
<dd>If you miss a dose of valganciclovir, take the missed dose as soon as you remember. Then, take the next dose at the usual scheduled time. However, if it is almost time for your next dose, <span class="Bold">do not take the missed dose. </span>
</dd>
<dt>•</dt>
<dd>Do not let your valganciclovir run out. The amount of virus in your blood may increase if your medicine is stopped, even for a short time. </dd>
<dt>•</dt>
<dd>If you take too much valganciclovir, call your local poison control center or emergency room right away. You may need treatment in a hospital. </dd>
<dt>•</dt>
<dd>Do not substitute valganciclovir tablets for ganciclovir capsules. Talk to your doctor, nurse or pharmacist if you have questions about your medicine. </dd>
</dl>
<p><span class="Bold">What should I avoid while taking valganciclovir? </span></p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Valganciclovir can cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, unsteady movements, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>. You should not drive a car or operate other dangerous machinery until you know how valganciclovir affects you. </span> </dd>
</dl>
<p><span class="Bold">What are the possible side effects of valganciclovir? </span><br><span class="Bold">Valganciclovir may cause serious side effects, including: </span></p>
<dl>
<dt>•</dt>
<dd>See “<span class="Bold">What is the most important information I should know about valganciclovir?</span>? <span class="Bold"> </span>
</dd>
</dl>
<p><span class="Bold">Common side effects of valganciclovir in adults and children include: </span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </dd>
<dt>•</dt>
<dd>shaky movements (<span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>) </dd>
<dt>•</dt>
<dd>low white cell, red cell and platelet cell counts in blood tests </dd>
<dt>•</dt>
<dd>rejection of the transplanted organ (graft)  </dd>
</dl>
<p><span class="Bold">Other common side effects in children include: </span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> </dd>
<dt>•</dt>
<dd>high blood pressure </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">colds</span>  </dd>
</dl>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.  <br>These are not all the possible side effects of valganciclovir. For more information, ask your doctor or pharmacist.  <br>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.  </p>
<p><span class="Bold">How should I store valganciclovir tablets? </span></p>
<dl>
<dt>•</dt>
<dd>Store valganciclovir tablets at room temperature between, 20°C-25°C (68°F-77°F) </dd>
<dt>•</dt>
<dd>Do not keep medicine that is out of date or that you no longer need. </dd>
<dt>•</dt>
<dd>
<span class="Bold">Keep valganciclovir tablets and all medicines out of the reach of children. </span> </dd>
</dl>
<p><span class="Bold">General information about valganciclovir  </span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use valganciclovir for a condition for which it was not prescribed. Do not give valganciclovir to other people, even if they have the same symptoms you have. It may harm them.<br>This leaflet summarizes the most important information about valganciclovir. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about valganciclovir that is written for health professionals.  <br>For more information about valganciclovir call 1-888-375-3784.  </p>
<p><span class="Bold">What are the ingredients in valganciclovir tablets?</span></p>
<p><span class="Bold">Active Ingredient: </span>valganciclovir hydrochloride USP  </p>
<p><span class="Bold">Inactive Ingredients for Tablets: </span>crospovidone, magnesium stearate, microcrystalline cellulose and povidone. The film-coat applied to the tablets contains hypromellose, iron oxide red, polyethylene glycol, polysorbate and titanium dioxide. <br>To reorder additional Patient Information Sheets, contact American Health Packaging at 1-800-707-4621.</p>
<p>Rx Only </p>
<p>Packaged and Distributed by: <br><span class="Bold">American Health Packaging</span><br>Columbus, OH 43217 </p>
<p>8296525/1214</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="_16210b34-c4fd-6e89-fd8a-a33883f0b2db"></a><a name="section-18"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure">
<a name="id2541"></a><img alt="VALGANCICLOVIR TABLETS, USP 450 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4db6dd63-e56b-45a4-86b2-ee125a1854a0&amp;name=Carton.jpg">
</div>
<p class="First"><span class="Bold">NDC 68084-965-25</span></p>
<p><span class="Bold">VALGANCICLOVIR</span><br>Tablets, USP</p>
<p><span class="Bold">450 mg*</span></p>
<p><span class="Bold">30 Tablets (5 × 6)</span></p>
<p><span class="Bold">PHARMACIST:</span> Dispense with the accompanying<br>Patient Information Leaflet to each patient.</p>
<p><span class="Bold">*Each Film-Coated Tablet Contains:</span><br>Valganciclovir Hydrochloride USP equivalent to <br>Valganciclovir 450mg.</p>
<p><span class="Bold">DO NOT BREAK OR CRUSH TABLETS</span></p>
<p><span class="Bold">Usual Dosage:</span> See package insert for full<br>prescribing information</p>
<p><span class="Bold">CAUTION: Strict adherence to dosage <br>recommendations is essential to avoid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</span></p>
<p><span class="Bold">Store</span> at 20º to 25ºC (68º to 77ºF); excursions<br>permitted to 15º to 30ºC (59º to 86ºF) [see USP<br>Controlled Room Temperature].</p>
<p><span class="Bold">Keep this and all drugs out of reach of children.</span></p>
<p><span class="Bold">Rx Only</span></p>
<p>The drug product contained in this package is from<br>NDC # 55111-762, Dr. Reddy’s Laboratories Limited.</p>
<p>Packaged and Distributed by: <br>American Health Packaging                         <br>Columbus, Ohio 43217        </p>
<p>096525<br>Rev. 12/2014</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VALGANCICLOVIR 		
					</strong><br><span class="contentTableReg">valganciclovir tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68084-965(NDC:55111-762)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>VALGANCICLOVIR HYDROCHLORIDE</strong> (Ganciclovir) </td>
<td class="formItem">Valganciclovir</td>
<td class="formItem">450 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 20</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RDY;762</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68084-965-25</td>
<td class="formItem">30  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68084-965-95</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203511</td>
<td class="formItem">01/15/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>American Health Packaging
							(007914906)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">American Health Packaging</td>
<td class="formItem"></td>
<td class="formItem">929561009</td>
<td class="formItem">REPACK(68084-965)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4db6dd63-e56b-45a4-86b2-ee125a1854a0</div>
<div>Set id: 4db6dd63-e56b-45a4-86b2-ee125a1854a0</div>
<div>Version: 1</div>
<div>Effective Time: 20150114</div>
</div>
</div> <div class="DistributorName">American Health Packaging</div></p>
</body></html>
